   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
 1     COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 People
 2     Spencer C. Knight*1, Shannon R. McCurdy*1, Brooke Rhead1, Marie V. Coignet1, Danny S.
 3     Park1, Genevieve H.L. Roberts2, Nathan D. Berkowitz1, Miao Zhang1, David Turissini1, Karen
 4     Delgado2, Milos Pavlovic2, AncestryDNA Science Team2, Asher K. Haug Baltzell2, Harendra
 5     Guturu1, Kristin A. Rand1, Ahna R. Girshick1, Eurie L. Hong1, Catherine A. Ball1
 6
 7     *These authors contributed equally to this work.
 8     1. AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107
 9     2. AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043
10     Corresponding Author: Catherine Ball, cball@ancestry.com
11
12     Abstract
13     The growing toll of the COVID-19 pandemic has heightened the urgency of identifying
14     individuals most at risk of infection and severe outcomes, underscoring the need to assess
15     susceptibility and severity patterns in large datasets.1 The AncestryDNA COVID-19 Study
16     collected self-reported survey data on symptoms, outcomes, risk factors, and exposures for over
17     563,000 adult individuals in the U.S., including over 4,700 COVID-19 cases as measured by a
18     self-reported positive nasal swab test. We observed significant associations between several risk
19     factors and COVID-19 susceptibility and severity outcomes. Many of the susceptibility
20     associations were accounted for by differences in known exposures; a notable exception was
21     elevated susceptibility odds for males after adjusting for known exposures and age. We also
22     leveraged the dataset to build risk models to robustly predict individualized COVID-19
23     susceptibility (area under the curve [AUC]=0.84) and severity outcomes including
24     hospitalization and life-threatening critical illness amongst COVID-19 cases (AUC=0.87 and
25     0.90, respectively). The results highlight the value of self-reported epidemiological data at scale
26     to provide public health insights into the evolving COVID-19 pandemic.
27
                                                                             1
           NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
28     Main
29     The COVID-19 pandemic has resulted in nearly 35 million COVID-19 cases and more than
30     1,000,000 deaths worldwide,2 including nearly 7.5 million cases and more than 210,000 deaths in
31     the United States as of early October 2020.3 The growing impact of the pandemic intensifies the
32     need for enhanced understanding of COVID-19 susceptibility and severity risk factors, not only
33     for public health experts, but also for individuals seeking to assess their own personalized risk.
34     Prior research has hypothesized that differences in COVID-19 susceptibility are related to age,4
35     sex-dependent immune responses,5 and genetics,6,7 while heightened severity of COVID-19
36     illness is associated with risk factors such as age,1,4,8,9 sex,5,10â€“12 underlying health
37     conditions,1,9,10,13,14 and genetic factors including the ABO blood group.15 Self-reported survey
38     data, which can easily be collected in the home, afford the opportunity to dynamically monitor
39     the continually evolving pandemic and allow for real-time estimation of individual-level
40     COVID-19 risk.16â€“19 Furthermore, self-reported surveys allow for collection of information about
41     known exposures, of which few epidemiological COVID-19 studies have explicitly accounted
42     for in association analyses to date.20
43
44     In this paper, we aim to provide insight into factors associated with susceptibility and severity of
45     COVID-19 using a large survey cohort of 563,141 AncestryDNA customers who have consented
46     to participate in the AncestryDNA COVID-19 Study (Supplementary Tables 1-6).6 We found
47     that known exposure differences account for many associations for a positive COVID-19 test
48     result.18,21 Further analysis yielded evidence that males may be more susceptible to COVID-19
49     than females after adjusting for known exposures and age. While several previous reports have
50     documented increased severity risk in males,5,11,13 the finding of sex-based differences in
                                                                          2

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
51     susceptibility here warrants further investigation. This study also replicates previous reports of
52     strong associations between certain health conditions, age, and COVID-19 severity,1,8â€“14 many of
53     which remain significant after adjusting for other risk factors. We additionally investigated the
54     symptomotology of COVID-19, and found that the symptoms most strongly associated with a
55     positive test result are distinct from the symptoms most strongly associated with severity.17,18,22,23
56
57     Finally, we built predictive risk models for COVID-19 susceptibility and severity outcomes. For
58     susceptibility, we designed two models and additionally applied two literature-based models18 to
59     predict COVID-19 cases among respondents reporting a test result. We also designed models to
60     predict two different COVID-19 severity outcomes based on minimal information about
61     demographics, health conditions, and symptoms: hospitalization due to COVID-19 infection
62     (referred to throughout as â€œhospitalizationâ€) and progression of an infection to a life-threatening
63     critical case among those reporting a positive COVID-19 result (referred to throughout as
64     â€œcritical caseâ€; Methods).13 All of the susceptibility and severity models performed robustly
65     when evaluated in a large internal holdout dataset, and could potentially serve as tools for
66     understanding individualized COVID-19 susceptibility and severity risk.1,16â€“19,24 Assessing
67     model performance in different populations offers insight into how well a risk model may
68     generalize to the broader population. We assessed all of the risk models across different age, sex
69     and genetic ancestry cohorts, and we report reasonably high performance in all cohorts.
70
71     Survey description. Survey responses were collected from AncestryDNA customers (see
72     Methods and Supplementary Table 3 for demographic information). The survey collected self-
73     reported responses to questions about COVID-19 test results, 15 symptoms among those who
74     tested positive or who tested negative and had flu-like symptoms, disease progression for
                                                                          3

   medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
     (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                         It is made available under a CC-BY-NC-ND 4.0 International license .
75     positive testers, age, height, weight, known exposures to biological relatives, household
76     members, patients or any other contacts with COVID-19, and 11 underlying health conditions
77     (Supplementary Tables 1 and 2). Data were collected between 22 April 2020 and 6 July 2020,
78     and the survey completion rate was approximately 95%. In general, the COVID-19 positive test
79     rate and self-reported clinical outcomes are consistent with those reported by the U.S. Centers for
80     Disease Control and Prevention (CDC) over a similar period (Supplementary Note 1).21
81
                                                                          4

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
 82     Association Analyses
 83     Susceptibility. We investigated associations between COVID-19 testers reporting a positive or
 84     negative result and risk factors within the dataset (Figure 1, Methods, Supplementary Tables 7-
 85     12). Unadjusted odds ratios (ORs) were calculated using simple logistic regression, and adjusted
 86     ORs (aORs) were calculated using multiple logistic regression including known exposures, age,
 87     and sex as risk factors. Unadjusted ORs provide insight into which individual variables are
 88     correlated with testing positive for COVID-19, while adjusted ORs provide insight into which of
 89     these associations are not completely explained due to differences in age, sex, and known
 90     exposures.25
 91     Known COVID-19 exposures, either through a household case (OR=26.03; 95% confidence
 92     interval [CI]=(22.26, 30.43)), biological relative (OR=5.77; 95% CI=(4.99, 6.68)), or other
 93     source of â€œdirectâ€ exposure (OR=6.94; 95% CI=(6.02, 7.99)) were the strongest predictors of a
 94     positive COVID-19 test result (Figure 1, Supplementary Table 7). In general, adjusting for
 95     known exposures, age, and sex resulted in attenuation of the ORs, with many associations
 96     becoming insignificant after adjustment (Figure 1, Supplementary Tables 8-9). Intriguingly, the
 97     OR for males was not attenuated after adjustment, and males remained at elevated odds after
 98     adjusting for known exposures and age (aOR=1.36; 95% CI=(1.19, 1.55);                                                Figure 1,
 99     Supplementary Table 9). We also note that males and females reported comparable exposure
100     burden, with males slightly more likely to report a household case of COVID-19 but less likely
101     to report a case of COVID-19 among biological relatives (Supplementary Tables 11-12).
102
                                                                           5

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
103     Younger individuals (ages 18-29; OR=1.51; 95% CI=(1.26, 1.81)), as well as individuals of
104     admixed African-European (OR=1.48; 95% CI=(1.18, 1.85)) or admixed Amerindian ancestry
105     (OR=1.49; 95% CI=(1.26, 1.77)) were significantly more likely to test positive compared to
106     older individuals (ages 50-64, the largest age group in this cohort) or those of European ancestry,
107     respectively (Supplementary Table 7). These individuals reported higher levels of COVID-19
108     cases within the household, cases among biological relatives, and/or other known â€œdirectâ€
109     COVID-19 exposures (Supplementary Tables 10-12).26â€“30 Adjusting for age (ancestry groups
110     only), sex, and known exposures attenuated the OR for all three of these groups (younger
111     aOR=1.28; 95% CI=(1.03, 1.59), African-European aOR=1.23; 95% CI=(0.94, 1.62), and
112     Amerindian aOR=1.27; 95% CI=(1.04, 1.57); Figure 1, Supplementary Table 9).
113
114     Individuals reporting pre-existing medical conditions (e.g., cancer, cardiovascular disease,
115     chronic kidney disease [CKD], diabetes, hypertension) were less likely to test positive for
116     COVID-19 (Figure 1, Supplementary Table 7). We observed significantly decreased odds of a
117     known â€œdirectâ€ exposure to COVID-19, as well as significantly decreased odds of a household
118     case of COVID-19, among such individuals relative to those without any health conditions
119     (OR=0.71; 95% CI=(0.65, 0.78) and OR=0.74; 95% CI=(0.65, 0.84), respectively;
120     Supplementary Tables 10-11). Notably, individuals with asthma and those with other lung
121     conditions had significantly decreased odds of testing positive after adjusting for known
122     exposures, age, and sex (OR=0.82; 95% CI=(0.69, 0.97) and OR=0.67; 95% CI=(0.44, 1.00),
123     respectively; Supplementary Table 9).
124
                                                                           6

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
125     Severity. We investigated associations between demographics, exposures, symptoms, and
126     underlying health conditions for hospitalization and critical illness progression among COVID-
127     19 cases (Figure 2, Supplementary Figure 1). Consistent with previous reports,1,9,12â€“14 we
128     observed positive associations between certain health conditions and COVID-19 severity
129     outcomes; many of these associations remained significant after adjustment for age, sex, and
130     obesity (BMI >= 30) (Figure 2, Supplementary Tables 13-16). COVID-19 cases reporting at least
131     one underlying health condition were significantly more likely to progress to a critical case
132     (OR=2.85; 95% CI=(1.78, 4.57); Figure 2, Supplementary Figure 1, Supplementary Table 15).
133     Specific underlying health conditions that were associated with hospitalization and/or critical
134     case progression included CKD, chronic obstructive pulmonary disease (COPD), diabetes,
135     cardiovascular disease, and hypertension (Figure 2, Supplementary Figure 1, Supplementary
136     Tables 13 and 15). Among individuals testing positive for COVID-19, the oldest (â‰¥65 years)
137     were significantly more likely to be hospitalized compared to those aged 50-64 (OR=1.70; 95%
138     CI=(1.13, 2.56); Figure 2, Supplementary Table 13). Individuals of admixed African-European
139     ancestry who tested positive were significantly more likely to report progression to a critical
140     case, compared to those with European ancestry (OR=2.07; 95% CI=(1.03, 4.17); Supplementary
141     Figure 1, Supplementary Table 15). Among COVID-19 cases, males were significantly more
142     likely than females to report progression to a critical case (OR=1.54, 95%; CI=(1.00, 2.37);
143     Supplementary Figure 1, Supplementary Table 15); these findings are consistent with CDC
144     reports of increased ICU admittance rates in males (3% vs. 2%).21
145
                                                                           7

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
146     Differential symptomology. Among symptomatic people who were reported a COVID-19 test
147     result, those reporting moderate to severe change in taste or smell (OR=7.26; 95% CI=(5.54,
148     9.50)), fever (OR=1.60; 95% CI=(1.28, 2.01)), or feeling tired or fatigue (OR=1.41; 95%
149     CI=(1.05, 1.89)) were more likely to test positive (Figure 3, Supplementary Table 7). Those
150     reporting moderate to severe runny nose (OR=0.59; 95% CI=(0.47, 0.75)) or sore throat
151     (OR=0.49; 95% CI=(0.39, 0.62)) were more likely to test negative, consistent with previous
152     reports that these symptoms are more indicative of influenza or the common cold (Figure 3,
153     Supplementary Table 7).17,18,22 Change in taste or smell, a hallmark symptom of COVID-19
154     infection, was not associated with hospitalization (OR=0.77, 95% CI=(0.55, 1.07); Figure 3,
155     Supplementary Table 13). By contrast, dyspnea (shortness of breath) was the most predictive of
156     hospitalization and critical case progression (OR=7.52; 95% CI=(4.92, 11.49) and OR=11.55;
157     95% CI=(5.91, 22.59), respectively),23 but was not associated with a positive test result
158     (OR=1.14; 95% CI=(0.91, 1.44); Figure 3, Supplementary Tables 7, 13, and 15).
159
                                                                           8

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
160     Predictive risk models. We developed models that predict an individualâ€™s COVID-19 risk
161     (positive test result or severity). Many predictive models for COVID-19 infection and severity
162     outcomes have been reported in the literature.1,16â€“18,24,31 To date, few large-scale studies have
163     investigated both susceptibility and severity risk within the same dataset, offering a consistent
164     and comprehensive understanding of similarities and differences between the two outcomes.
165     For each of the risk models we developed, the survey data were divided into independent training
166     and test cohorts, and additional association analyses were performed on the training data to guide
167     the selection of risk factors for the models (Methods, Supplementary Tables 17-20). In contrast
168     to association analyses, these risk models are based on penalized logistic regression with cross-
169     validation in order to allow for transferability to independent cohorts.
170     The susceptibility models were designed to predict a COVID-19 result (positive or negative)
171     from risk factors among testers. In addition to our own two models, we also replicated two self-
172     reported models from the literature in order to assess how well our models perform relative to a
173     respected benchmark.18 In all, we compared four models: our model based on demographics and
174     exposures (referred to throughout as â€œDem + Expâ€); our model based on demographics,
175     exposures, and symptoms (referred to throughout as â€œDem + Exp + Sympâ€); and the two
176     literature-based models designed with nearly identical risk factors as reported previously in
177     another large, self-reported study (â€œHow We Feelâ€ (HWF); models referred to as â€œHWF Exp +
178     Sympâ€ and â€œHWF Sympâ€ throughout; Supplementary Note 2, Supplementary Table 20).18
179
180     All four susceptibility models performed robustly, with the Dem + Exp + Symp model achieving
181     the highest overall performance (Figure 4, Supplementary Tables 21-24). The three models that
                                                                           9

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
182     included one or more symptoms outperformed the model without symptoms (Dem + Exp),
183     underscoring the value of self-reported symptoms for discriminating between cases and controls.
184     The Dem + Exp model had an area under the curve (AUC) of 0.84 +/- 0.02, and the most
185     predictive risk factor was having a household case of COVID-19. The Dem + Exp + Symp
186     model had an AUC of 0.94 +/- 0.02, and the most predictive symptom was change in taste or
187     smell. The HWF Exp + Symp model had an AUC of 0.90 +/- 0.03, and the HWF Symp model
188     had an AUC of 0.87 +/- 0.03 (Supplementary Note 3). Each of the models performed comparably
189     across different age, sex, and genetic ancestry cohorts (Figure 4, Supplementary Tables 21-24).
190     We observed no significant overfitting in any of the models as evidenced by comparable train-
191     test performances (Supplementary Table 25).
192
193     We also trained severity models to predict hospitalization and critical illness progression among
194     COVID-19 cases. We included a number of risk factors and symptoms most associated with
195     severe COVID-19 outcomes from the literature and/or our training dataset (Figure 3,
196     Supplementary Tables 18 and 19); these included age,1,8,9,13 sex,1,5,11â€“13 morbid obesity (BMI >=
197     40),1,32 and health conditions,1,9,12â€“14 as well as shortness of breath,23 fever, feeling tired or
198     fatigue, dry cough, and diarrhea for symptoms. Both models performed robustly on an
199     independent holdout dataset (Figure 4). The hospitalization model had an AUC of 0.87 +/- 0.03,
200     and the critical case model had an AUC of 0.90 +/- 0.03. For both severity models, shortness of
201     breath was the most predictive risk factor. We were concerned that this might seem obvious, so
202     we designed models excluding this symptom which also achieved moderately high
203     discriminative performance (AUC > 0.80; Supplementary Figure 5). The severity models
204     performed comparably when stratifying by age, sex, and genetic ancestry (Figure 4,
                                                                          10

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
205     Supplementary Tables 26-27), and there was no significant overfitting bias as evidenced by
206     comparable train-test performances (Supplementary Table 25).
207
208     In contrast with susceptibility models, we did not evaluate the severity models against literature-
209     based models, as the vast majority of these models include clinical factors (e.g., bloodwork) not
210     measured in this self-reported dataset.1,16,31 However, the models presented here perform on par
211     with many previously reported models despite the absence of clinical factors, suggesting the
212     potential value of self-reported data to identify the most at-risk COVID-19 individuals.16,31
213
214     Discussion. The AncestryDNA COVID-19 Study provides a highly complete, self-reported
215     dataset that contains information about a plethora of risk factors in the context of COVID-19
216     susceptibility and severity outcomes. The self-report framework provides fast, low-cost,
217     population-scale data that are particularly valuable in a pandemic, where knowledge is both
218     limited and evolving rapidly based on changing circumstances. Additionally, the broad collection
219     mechanism enables data-gathering from many more and potentially more diverse participants
220     than typically seen in a medical setting, and participants can safely provide data from their
221     homes. Moreover, self-reported data have been shown to be useful for estimating population
222     prevalence,19 and models built from these data may help to contextualize individual risk prior to
223     infection with COVID-19.1,16â€“18,24,31
224
225     The study highlights exposure burden as the primary risk factor for COVID-19 susceptibility,
226     and the importance of accounting for known exposures when assessing differences in
227     susceptibility to COVID-19. Few studies have measured and explicitly adjusted for known
                                                                          11

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
228     COVID-19 exposures at this scale.20 We found elevated exposure levels for younger individuals,
229     as well as individuals of admixed African-European or admixed Amerindian ancestry, which
230     account for at least some of the elevated susceptibility risk for these individuals as evidenced by
231     attenuation of ORs after adjustment for known exposures and age. This finding is consistent with
232     previous reports about elevated exposure levels for younger and minority groups within the
233     U.S.26â€“30 By contrast, we found reduced exposure levels among those reporting one or more pre-
234     existing health conditions. The lower exposure burden observed for these individuals may reflect
235     pre-pandemic differences in public interactions or increased precautions to mitigate exposure,
236     given published severity risks associated with these conditions.1,9,13,14,33,34
237
238     Importantly, we found elevated susceptibility risk in males after adjusting for age and known
239     exposures, and the adjusted odds were not attenuated compared to the unadjusted odds. This
240     finding is distinct from previous findings on elevated severity risk in males.1,5,11 This result could
241     be due to differences between men and women in behaviors, unknown exposures, biology,
242     genetics,5â€“7 or other risk factors not measured within this dataset.
243
244     Another major contribution of this study is the development of novel risk models for predicting
245     an individualâ€™s COVID-19 susceptibility and severity risk. The risk models presented here
246     perform comparably or better than similar and more complex models reported previously.16â€“
        18,24,31
247              Although some previously reported risk models have been assessed in different age or sex
248     cohorts,16,17 we are not aware of any that have been assessed across genetic ancestry cohorts,1,16â€“
        18,24,31
249              highlighting the potential utility and generalizability of these models to the broader
250     population. Such models may be useful to clinicians to estimate an individualâ€™s risk of infection
                                                                          12

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
251     and/or severity risk, or as a potential tool to triage testing given limited resources.17,18,22 Just as
252     importantly, the models could also be used by public health experts to understand population-
253     level risk at large, given minimal self-reported risk factor data.
254
255     The COVID-19 pandemic has exacted a historic toll on healthcare systems and global
256     economies, and continues to evolve based on changes in human behavior, public health
257     guidelines, and societal factors. The large AncestryDNA network, well-established data
258     collection mechanisms, and willingness of AncestryDNA customers to participate in COVID-19
259     research have rapidly come together in this study to elucidate more details about susceptibility
260     and severe disease risk factors and help point the way to minimizing disease burden.
261
262
                                                                          13

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
263     Methods
264     Ethics statement. Ethics statement. All data for this research project were from subjects who
265     have provided informed consent to participate in AncestryDNA's Human Diversity Project, as
266     reviewed and approved by our external institutional review board, Advarra (formerly Quorum).
267     All data were de-identified prior to use.
                                                                          14

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
268     Study population. Collection of self-reported COVID-19 outcomes from AncestryDNA
269     customers who consented to research, participation criteria for the study, and the survey design
270     are described in a genome-wide association study (GWAS) on a very similar AncestryDNA
271     dataset, which identified three novel, genome-wide significant loci.6 Here, participants reporting
272     a negative test result were also assessed for symptoms and clinical outcomes. Analyses presented
273     here were performed with data collected between 22 April and 6 July 2020.
274     Outcome definitions. The study assessed three outcomes: one for susceptibility and two for
275     severity of COVID-19 infection. Cases for COVID-19 susceptibility were individuals who
276     responded, â€œYes, and was positiveâ€ to the question, â€œHave you been swab tested for COVID-19,
277     commonly referred to as coronavirus?â€ Responders who answered, â€œYes, and was negativeâ€
278     were used as controls for the susceptibility analysis.
279     The hospitalization outcome was defined among COVID-19-positive cases if a participant
280     responded "Yes" to a binary question about experiencing symptoms due to COVID-19 illness
281     and "Yes" to the hospitalization question ("Were you hospitalized due to these symptoms?).
282     Controls were defined by a response of â€œNoâ€ to the hospitalization question in addition to
283     reporting a self-reported positive COVID-19 test result.6
284
285     Critical cases of COVID-19 were defined via a response of â€œYesâ€ to one or more questions about
286     ICU admittance (â€œWere you hospitalized in the Intensive Care Unit [ICU] with a ventilator?â€ or
287     â€œWere you hospitalized in the Intensive Care Unit [ICU] with oxygen?â€) or, alternatively, self-
288     reported septic shock, organ failure, or respiratory failure resulting from a COVID-19 infection
289     (â€œHave you had any of the following complications due to your illness? Select all that apply.â€).13
                                                                          15

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
290     Controls were defined by a response of â€œNoâ€ across all of these questions in addition to self-
291     reporting a positive COVID-19 test result.
292
293     Genetic sex and ancestry definitions. All individuals were genotyped, using previously
294     described general genotyping and quality control procedures.35 Both sex and genetic ancestry
295     were defined for individuals based on their genotypes. Genetic ancestry was estimated using a
296     proprietary algorithm to estimate continental admixture proportions.36 Briefly, this algorithm
297     uses a hidden Markov model to estimate unphased diploid ancestry across the genome by
298     comparing haplotype structure to a reference panel.
299
300     Data preparation for analysis. Multiple-choice categorical questions were one-hot (â€œdummyâ€)
301     encoded as binary risk factors with k-1 degrees of freedom, where k corresponds to the number
302     of fields for a given question. In this framework, a value of 0 across all k-1 fields corresponds to
303     a response of â€œNoneâ€ or â€œNone of the aboveâ€ for a given question.
304
305     We considered several risk factors and outcomes questions in our association analyses and risk
306     modeling efforts, some of which are summarized in Supplementary Tables 1 and 2. Based on the
307     dependency structure within our survey, not every question was surfaced to every participant
308     included within our study. As such, we made the following inferences:
309          â— Participants reporting â€œNoâ€ to a binary question about symptoms arising from COVID-19
310               infection (â€œDid you experience symptoms as a result of your condition?â€) were
311               designated as negatives for dependent questions about individual symptoms (â€œBetween
312               the beginning of February 2020 and now, have you had any of the following
                                                                          16

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
313               symptoms?â€), hospitalization due to symptoms (â€œWere you hospitalized due to these
314               symptoms?â€), ICU admittance due to symptoms (â€œWere you hospitalized in the Intensive
315               Care Unit [ICU] with a ventilator?â€ or â€œWere you hospitalized in the Intensive Care Unit
316               ([ICU] with oxygen?â€), and medications prescribed due to symptoms (â€œDid a doctor treat
317               you with medication for your illness?â€)
318          â— Participants reporting â€œNoâ€ to a binary question about hospitalization (â€œWere you
319               hospitalized due to these symptoms?â€) were assigned to a hospital duration of 0 days and
320               designated as negative for ICU admittance due to symptoms.
321          â— Participants reporting â€œNoâ€ to a binary question about medications prescribed due to
322               symptoms (â€œDid a doctor treat you with medication for your illness?â€) were designated as
323               negative for individual medication fields from a dependent question ("What medication
324               were you treated with?â€).
325
326     Responses to a question about individual symptoms (â€œBetween the beginning of February 2020
327     and now, have you had any of the following symptoms?â€) were converted to a binary variable
328     based on the following mapping: 0 = None, Very Mild, Mild; 1 = Moderate, Severe, Very
329     Severe.
                                                                          17

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
330     Association analysis. Analyses were performed either with the statsmodels package in Python3
331     or in base R with the glm function. For each susceptibility and severity outcome and risk factor
332     of interest, a simple logistic regression (LR) model was fit using unpenalized maximum
333     likelihood.37 LR models were fit on the entire cohort, except for age, sex, genetic ancestry, and
334     obesity, where the models were fit only on the appropriate reference population drawn from the
335     entire cohort (Supplementary Tables 7-16). Multiple logistic regression was used to adjust the
336     ORs for known COVID-19 exposures and potentially confounding risk factors. The adjusted
337     model includes age, sex, and four known exposures for susceptibility outcomes (Y/N if any); and
338     age, sex, obesity (binarized if BMI >= 30), and health conditions (binarized if any) for severity
339     outcomes (Figures 1 and 2). Individual adjustment variables were omitted when analyzing
340     associations for risk factors within equivalent categories (e.g., age was not included in adjusted
341     models for age bin risk factors).
342
343     For each risk factor, 95% confidence intervals (CIs) for the log odds ratio were estimated under
344     the normal approximation. The significance threshold was Bonferroni-corrected for the 42
345     different risk factors examined, leading to an adjusted threshold of 0.05/42=0.0012.37
346
                                                                          18

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
347     Risk model training and evaluation
348     Data splitting. All data were used in the OR analyses; data splitting was performed for risk
349     modeling only. Prior to model training, the data were split with a fixed random seed. For
350     susceptibility models without symptoms, 75% of the data were used for model training and 25%
351     of the data were used for holdout evaluation. For severity models and susceptibility models with
352     symptoms, 50% of the data were used for model training and 50% of the data were used for
353     holdout evaluation. The larger holdout set allows for more robust stratified analyses of model
354     performances, given the smaller overall cohort sizes for models with symptoms.
355
356     Predictive risk models. Logistic regression models were trained and evaluated using the scikit-
357     learn package in Python. Here, we used lasso-penalized multiple logistic regression with cross-
358     validation on the training dataset in order to select an optimal hyperparameterization for
359     generalizability to independent test sets.37 The penalized objective function for regression was
360     weighted by inverse prevalence to address class imbalance and was framed as follows:
361
                                     à¬µ à¯           à¯                                      à¯ 
362                             âˆ‘
                                    à¯  à¯à­€à¬µ à¯ à³¤à°¸à³¤à³•         à¯   Â· à¢   à¯          1       à¯  1   Â· à¢  
                                                                                       à³¤à°¸à³¤à³•
                                    à°’ à¯¡
363                                    âˆ‘ | |
                                    à¯  à¯œà­€à¬´ à¯œ
364
365     where m is the number of training examples, yj is the true value of the outcome variable for the
366     jth observation within the training data, my=yj is the number of training examples with y=yj, Î²
367     corresponds to the vector of estimated coefficients for the risk factors, xj is the vector of risk
368     factor values for the jth observation within the training data, Logistic is the logistic (sigmoid)
369     function, Î» is the regularization parameter which favors simpler models via shrinkage of the beta
                                                                          19

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
370     coefficients, n is the total number of risk factors in the model, Î² i is the regression coefficient for
371     the ith risk factor in the model, and Ln is the natural logarithm.
372     Risk factor selection and model training. We chose risk factors based on a minimal subset of
373     nominally significant ORs within our training data as well as literature guidance.1,4,5,9,11â€“14 For
374     the susceptibility models without symptoms, we included a subset of exposure-related questions,
375     based on the training OR analyses, as well as two demographic variables (age and sex). For
376     susceptibility models with symptoms, we additionally included the five symptoms most
377     differentiated between symptomatic negative and positive testers from our training ORs. For the
378     severity models, we included pre-existing conditions, based on the training OR analyses,
379     predictive symptoms within our training dataset36, morbid obesity (BMI >= 40), age, and sex.
380     The full list of risk factors for each model is included in Supplementary Table 20.
381
382     Once final risk factors were selected, we performed 5-fold cross-validation with grid search on
383     our training dataset to select an optimal lasso regularization parameter lambda.37 For the grid
384     search, we scanned 8 different values for lambda, equally partitioned geometrically across a 4-
385     log space. We then re-trained on the entire training dataset with the optimal lambda, and
386     evaluated the final model on the holdout dataset.
387
388     Model thresholding. Phenotypes were predicted from the output of trained models based on a
389     50% probability threshold (i.e., logistic model output > 0.5). Sensitivity and specificity were then
390     calculated based on the true vs. predicted binary outcomes.
391
                                                                          20

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
392     Estimation of performance error. To estimate the error in our model performances, we
393     bootstrapped our holdout dataset 1,000 times to generate a sampling distribution for each
394     evaluation metric. We estimated the mean and 95% CIs for each metric based on the mean and
395     standard deviation of this sampling distribution.37
396
397     Figures, Tables, and Legends
398     Figures
399
                                                                          21

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
400     Figure 1: Odds ratio visualization for susceptibility
401
402
                                                                          22

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
403     Figure 1. Susceptibility odds ratios (ORs) and 95% confidence intervals (CIs) estimated
404     from simple (â€œUnadjusted models,â€ grey) and multiple (â€œAdjusted models,â€ black) logistic
405     regression with adjustment for other risk factors. Open circles indicate not significant (p-
406     value > 0.05) after accounting for multiple hypothesis tests using Bonferroni correction. Age,
407     sex, genetic ancestry, and obesity ORs were estimated in relation to the reference variables
408     indicated. Exposure, health, and symptom ORs were each estimated separately as binary
409     variables. Symptom ORs were estimated as binary variables among symptomatic testers only
410     (Methods). Risk factor adjustments for susceptibility include: sex, age, and at least one known
411     COVID-19 exposure (Methods). Where applicable, individual adjustment variables were omitted
412     to avoid duplicate adjustment (Methods).
413
414
                                                                          23

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
415     Figure 2: Odds ratio visualization for severity
416
417
418
                                                                          24

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
419     Figure 2. Severity (hospitalization) odds ratios (ORs) and 95% confidence intervals (CIs)
420     estimated from simple (â€œUnadjusted models,â€ grey) and multiple (â€œAdjusted models,â€
421     black) logistic regression with adjustment for other risk factors. Open circles indicate not
422     significant (p-value > 0.05) after accounting for multiple hypothesis tests using Bonferroni
423     correction. Age, sex, genetic ancestry, and obesity ORs were estimated in relation to the
424     reference variables indicated. Exposure, health, and symptom ORs were each estimated
425     separately as binary variables. Symptom ORs were estimated as binary variables among
426     symptomatic testers only (Methods). Risk factor adjustments for severity include: sex, age,
427     obesity (Y/N), and underlying health conditions (Y/N if any). Where applicable, individual
428     adjustment variables were omitted to avoid duplicate adjustment (Methods). See Supplementary
429     Figure 1 for critical case severity ORs.
430
                                                                          25

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
431     Figure 3: Comparison of susceptibility and severity adjusted ORs
432
433
434     Figure 3. Comparison of susceptibility adjusted ORs (horizontal axis) and severity adjusted                                      ed
435     ORs (vertical axis) for symptoms in Figures 1 and 2. Severity aORs are for hospitalization..
436     Note that aORs for susceptibility and severity are adjusted differently according to descriptions                                ns
437     in Figure 1 and 2 captions. Adjusted ORs are plotted on a log scale for visibility. Shortness of
438     breath is the strongest indicator of increased severity, while change in taste or smell is the                                   he
                                                                          26

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
439     strongest indicator for testing positive for COVID-19 among symptomatic individuals
440     (Methods). See Supplementary Figure 2 for demographic, health condition, and exposure aORs.
441
                                                                          27

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
442     Figure 4: Risk model performance
443
444
445     Figure 4. Performance of risk models on independent holdout data. a) Receiver operating                                          ng
446     characteristic (ROC) curves for susceptibility models to predict COVID-19 cases among testers                                   ers
447     reporting a result (positive or negative). b) Area under the curve (AUC) for the four                                             ur
448     susceptibility models in (a), stratified by cohort. â€œAllâ€ represents everyone in (a). c) ROC curves                               es
449     for severity models to predict either hospitalization (red) or critical illness progression (black)                               k)
                                                                          28

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
450     among COVID-19 cases. d) Area under the curve (AUC) for the two severity models in (b),
451     stratified by cohort. â€œAllâ€ represents everyone in (c). Refer to Methods as well as Supplementary
452     Figure 3 and Supplementary Tables 20-27 for additional model performance data and model risk
453     factor information.
454
455
                                                                          29

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
456     Data availability We plan to make a dataset available to qualified scientists through the
457     European Genome-phenome Archive (EGA). The EGA dataset includes the risk factors and
458     outcomes studied here, for a different set of individuals.
459     Acknowledgements We thank our AncestryDNA customers who made this study possible by
460     contributing information about their experience with COVID-19 through our survey. Without
461     them, this work would not be possible. We would like to thank Zach Bass, Robert Dowling,
462     Disha Akarte, Swapnil Sneham, Sean Enright and the entire Cyborg team for their tireless work
463     in the release and continued support of the COVID-19 survey.
464     Author contributions SCK and SRM contributed equally to the manuscript and wrote the first
465     draft of the paper. ARG provided direct project guidance and lead the COVID-19 research teams.
466     SCK, SRM, BR performed the association analyses. SCK developed and assessed the risk
467     models. MVC and KAR designed the COVID-19 survey questionnaire. SCK and DP supported
468     the dataset creation. GHLR supported the phenotype definitions. MVC and NDB built the
469     demographic tables. SCK, SRM, BR, MVC, GHLR, ARG, and KAR helped with additional
470     analyses and interpretation. MZ, DP, DT, KD, MP, HG, AKHB helped with the EGA dataset.
471     The AncestryDNA Science Team contributed to additional work, allowing for the completion of
472     the COVID-19 research and manuscript. KAR, ELH, and CAB provided additional project
473     guidance. All authors contributed to the final manuscript.
                                                                          30

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
474     Competing interests The authors declare competing financial interests: authors affiliated with
475     AncestryDNA may have equity in Ancestry.
476     AncestryDNA Science Team: Yambazi Banda, Ke Bi, Robert Burton, Marjan Champine, Ross
477     Curtis, Abby Drokhlyansky, Ashley Elrick, Cat Foo, Michael Gaddis, Jialiang Gu, Shannon
478     Hateley, Heather Harris, Shea King, Christine Maldonado, Evan McCartney-Melstad, Alexandra
479     McFarland, Patty Miller, Luong Nguyen, Keith Noto, Jingwen Pei, Jenna Petersen, Scott Pew,
480     Chodon Sass, Josh Schraiber, Alisa Sedghifar, Andrey Smelter, Sarah South, Barry Starr, Cecily
481     Vaughn, Yong Wang
                                                                          31

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
482     Supplementary Materials
483
484     Supplementary Notes
485
486     Supplementary Note 1. Comparison of AncestryDNA Data to CDC Data. In general, the
487     COVID-19 testing results are consistent with those reported by the U.S. Centers for Disease
488     Control and Prevention (CDC) over a similar period.21 For example, the CDC reported a 12%
489     cumulative overall positive test rate from 1 March to 30 May 2020, while 14.1% of
490     AncestryDNA survey participants reported testing positive (the denominator includes tests with
491     â€œresults pendingâ€). For hospitalization, the CDC reported that 14% of individuals testing positive
492     for COVID-19 were hospitalized, and 2% were admitted to an intensive care unit (ICU), between
493     22 January and 30 May 2020. Among the AncestryDNA survey respondents, 11% of those
494     reporting a positive COVID-19 test were hospitalized, and 4.9% were admitted to ICU between
495     22 April and 6 July 2020.
496
497     Supplementary Note 2. Risk factors for predictive susceptibility models. The HWF Exp +
498     Symp model includes three risk factors, including two exposures and one symptom (change in
499     taste or smell, Supplementary Table 20). The HWF Symp model includes seven symptoms most
500     commonly associated with COVID-19 according to the CDC (Supplementary Table 20).18,38 For
501     the Dem + Exp and Dem + Exp + Symp models, we incorporated responses to several exposure
502     questions that were primary risk factors in the OR analysis of the training set (Methods and
503     Supplementary Table 20).18,39,40 We also considered age and sex, given their nominal association
504     with COVID-19 in our ORs in the training dataset, as well as reports about these variables as
                                                                          32

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
505     risk factors (Supplementary Table 17).4,5,30 For Dem + Exp + Symp model, we selected the most
506     differentiated symptoms between cases and controls amongst symptomatic COVID-19 testers
507     within the training dataset (Supplementary Table 17), including fever, change in taste or smell,
508     feeling tired/fatigued, runny nose, and sore throat.17,18,22
509
510     Supplementary Note 3. Comparison of Ancestry and HWF Cohorts and Performances. The
511     HWF models performed better when trained and evaluated on the AncestryDNA dataset as
512     compared with the HWF dataset, particularly for the symptoms-only model (HWF Symp:
513     AncestryDNA-trained AUC=0.87 and HWF-trained AUC=0.76 and HWF Exp + Symp:
514     AncestryDNA-trained AUC=0.90 and HWF-trained AUC=0.87; Figure 4).18 This result could be
515     due to differences in survey flow design, demographics, or the relative prevalences of self-
516     reported symptoms between the two datasets. We re-trained and evaluated our models on a
517     subset of symptomatic COVID-19 testers (positives and negatives) reporting at least one
518     symptom of moderate or greater intensity. The performances of all models that included
519     symptoms were slightly attenuated in this cohort, with AUCs for the HWF models approaching
520     previous reports (HWF Symp: AncestryDNA-trained AUC=0.80 and HWF Exp + Symp:
521     AncestryDNA-trained AUC=0.87); the model without symptoms performed the same
522     (Supplementary Figure 4). This suggests that predicting COVID-19 cases on the basis of
523     symptoms alone is more challenging when symptoms are less differentiated between positive and
524     negative testers.
525
526
                                                                          33

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           It is made available under a CC-BY-NC-ND 4.0 International license .
527     Supplementary Tables
528     Supplementary Table 1. Selected subset of survey questions considered in the context of
529     COVID-19 severity outcomes analysis and modeling efforts.
530
        Risk factor
        description        Question                   Possible responses
                           Have you been swab        Yes, and was positive; Yes, and was negative; Yes, and my results are
                           tested for COVID-19,      pending; No, but I have had flu-like symptoms with a fever at some point
        COVID-19 test      commonly referred to      since the beginning of February 2020; No, and I have not had flu-like
        result             as coronavirus?           symptoms at some point since the beginning of February 2020
                           Have any of your
        Case amongst       biological relatives
        direct biological  tested positive for
        relatives (multi-  COVID-19? Select all
        choice)            that apply.               Grandparent(s); Parent(s); Child(ren); Sibling(s); Other; None
                           Are you a healthcare
                           professional working
                           directly with or in close
        Healthcare         physical proximity to
        worker routinely patients who have
        exposed to         tested positive for
        COVID-19           COVID-19?                 Yes; No; Not sure
                           Has someone in your
                           household tested
        Household case     positive for COVID-
        of COVID-19        19?                       Yes; No; Not sure
                           How many people in
        Number of          your household have
        household cases    tested positive for
        of COVID-19        COVID-19?                  Numeric
                           Have you been directly
        Known direct       exposed to someone
        COVID-19           who has tested positive
        exposure           for COVID-19?             Yes; No; Not sure
                                                     Asthma,COPD (Chronic Obstructive Pulmonary Disease); Other lung
                                                     condition; Cancer (treated in the past year); Cardiovascular disease; Chronic
                           Do you currently have     kidney disease; Diabetes; Hypertension; Organ failure requiring a transplant
                           any of the following      (in the last year); Blood disorder requiring hematopoietic stem cell / bone
        Health             health conditions?        marrow transplant; Other autoimmune disease; Other immunodeficiency
        condition(s)       Select all that apply.    disorder; Other; None; Not sure
531
532     The survey flow was as described previously,6 with the addition of symptom and clincial
533     assessment for negative testers.
                                                                                34

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
534     Supplementary Table 2. Selected risk factors considered in susceptibility or severity
535     outcomes analysis and modeling efforts.
536
        Risk factor
        description         Question                   Possible responses
                            Have you been swab         Yes, and was positive; Yes, and was negative; Yes, and my results are
                            tested for COVID-19,       pending; No, but I have had flu-like symptoms with a fever at some point
        COVID-19 test       commonly referred to as    since the beginning of February 2020; No, and I have not had flu-like
        result              coronavirus?               symptoms at some point since the beginning of February 2020
                            Did you experience
        Symptoms            symptoms as a result of
        (binary)            your condition?            Yes; No; Not sure
                            Between the beginning
                            of February 2020 and       Fever; Shortness of breath; Dry cough; Nasal congestion; Runny nose; Sore
                            now, have you had any      throat; Feeling tired or fatigue; Chills; Body aches; Headache; Cough
        Symptoms (multi- of the following              producing phlegm; Abdominal pain; Nausea or vomiting; Diarrhea; Change
        choice)             symptoms?                  in taste or smell
        Symptom
        duration (multi-    How long did these         Less than 1 day; 1-3 days; 4-7 days; 8-14 days; 2 weeks to a month; 1-3
        choice)             symptoms last?             months; More than 3 months
                            Were you hospitalized
        Hospitalization     due to these symptoms? Yes; No; Not sure
                            How long were you
        Hospital duration hospitalized?                Numeric
                            Were you hospitalized
                            in the Intensive Care
        ICU with            Unit (ICU) with a
        ventilator          ventilator?                Yes; No; Not sure
                            Were you hospitalized
                            in the Intensive Care
                            Unit (ICU) with
        ICU with oxygen     oxygen?                    Yes; No; Not sure
                            Have you had any of the
        Illness             following complications None; Pneumonia; Severe pneumonia leading to hospitalization;
        complications       due to your illness?       Respiratory failure; Septic shock; Multiple organ dysfunction or failure;
        (multi-choice)      Select all that apply.     Blood clots; Stroke; Other
537
538     The survey flow was as described previously,6 with the addition of symptom and clincial
539     assessment for negative testers.
540
541
542
                                                                                  35

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
543     Supplementary Table 3. Study population demographic summary
544
                                                                         COVID-19                 COVID-19
                                                                       Nasopharyngeal          Nasopharyngeal          Full AncestryDNA
                                                                          Swab Test               Swab Test            COVID-19 Cohort
                                                                            Positive               Negative
                                                                           n = 4,726              n = 28,872                n = 563,141
        Age
          Median, mean (sd)                                            49, 49.49 (15.43)        53, 52.68 (15.5)        56, 53.90 (16.13)
          Bins (Counts, %)
               18-30                                                       600 (0.13)             2496 (0.09)              52580 (0.09)
               31-40                                                       941 (0.2)              5001 (0.17)              87261 (0.15)
               41-50                                                       926 (0.2)              5333 (0.18)              90473 (0.16)
               51-60                                                     1057 (0.22)              6009 (0.21)             108062 (0.19)
               61-70                                                       735 (0.16)             5961 (0.21)             128200 (0.23)
               71-90                                                       467 (0.10)             4072 (0.14)              96565 (0.17)
        Genetic Sex (counts, %)
          Female                                                         3013 (0.64)             19945 (0.69)             380349 (0.67)
          Male                                                           1706 (0.36)              8867 (0.31)             183153 (0.32)
        Genetic Ancestry Continental Groupings
          Admixed African-European ancestry                                275 (0.06)             1244 (0.04)              17019 (0.03)
          Admixed Amerindian ancestry                                      520 (0.11)             2336 (0.08)              36865 (0.07)
          European ancestry                                               3026 (0.64)             20269 (0.7)             424328 (0.75)
          Other ancestry                                                   905 (0.19)             5023 (0.17)              84929 (0.15)
        Pre-existing health conditions (any)                             1911 (0.46)             15261 (0.55)             255788 (0.47)
        BMI (med, mean, sd)                                           28.59, 29.83 (7.04)     28.67, 29.92 (7.05)      28.29, 29.53 (6.87)
        Underweight (count, %)                                               <100                      204                      4407
        Healthy (count, %)                                                    971                      6442                   139565
        Overweight (count, %)                                                1225                      8503                   172941
        Obese (count, %)                                                     1629                    11264                    203325
        Flu
          Shot (yes)                                                     2656 (0.63)             19856 (0.71)             356144 (0.65)
          Test Dx (yes)                                                    198 (0.05)             1180 (0.04)              11726 (0.02)
        Symptoms (tested pos.)
          General, yes (count, % of pos.)                                3862 (0.87)                                        9237 (0.47)
        Hospitalization (count, % of positives)                            453 (0.11)                                       1397 (0.02)
          Duration, days (med, mean, sd)                                5, 7.62 (9.08)                                     3, 4.78 (7.22)
545
                                                                            36

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
546     Supplementary Table 4. Demographics for susceptibility modeling cohort
547
                                                                                                                               Total
                                                                                                  COVID-19
                                                                          COVID-19                                        Susceptibility
                                                                                               Nasopharyngeal
                                                                       Nasopharyngeal                                   modeling cohort
                                                                                                  Swab Test
                                                                     Swab Test Positive                                  (symptom data
                                                                                                   Negative
                                                                                                                          not required)
                                                                           n = 2,505              n = 16,830                n = 19,335
        Age
          Median, mean (sd)                                            48, 47.96 (14.68)        53, 52.93 (15.5)        53, 52.29 (15.49)
          Bins (Counts, %)
               18-30                                                       350 (0.14)             1404 (0.08)               1754 (0.09)
               31-40                                                       531 (0.21)             2882 (0.17)               3413 (0.18)
               41-50                                                       511 (0.2)              3073 (0.18)               3584 (0.19)
               51-60                                                       580 (0.23)             3478 (0.21)               4058 (0.21)
               61-70                                                       365 (0.15)             3548 (0.21)               3913 (0.20)
               71-90                                                       168 (0.07)             2445 (0.15)               2613 (0.14)
        Genetic Sex (counts, %)
          Female                                                          1646 (0.66)            11688 (0.69)              13334 (0.69)
          Male                                                             859 (0.34)             5142 (0.31)               6001 (0.31)
        Genetic Ancestry Continental Groupings
          Admixed African-European ancestry                                130 (0.05)              730 (0.04)                860 (0.04)
          Admixed Amerindian ancestry                                      287 (0.11)             1319 (0.08)               1606 (0.08)
          European ancestry                                               1633 (0.65)            11886 (0.71)              13519 (0.70)
          Other ancestry                                                   455 (0.18)             2885 (0.17)               3350 (0.17)
        Pre-existing health conditions (any)                              1131 (0.45)             9168 (0.54)              10299 (0.53)
        BMI (med, mean, sd)
          Total                                                        28.7, 29.95 (7.16)     28.52, 29.88 (6.99)      28.73, 30.02 (7.08)
        Underweight (count, %)                                                <100                     111                      135
        Healthy (count, %)                                                    629                      4051                     4680
        Overweight (count, %)                                                 759                      5433                     6192
        Obese (count, %)                                                      1069                     7012                     8081
        Flu
          Shot (yes)                                                      1617 (0.65)            12029 (0.71)              13646 (0.71)
          Test Dx (yes)                                                    125 (0.05)              761 (0.05)                886 (0.05)
        Symptoms (tested pos.)
          General, yes (count, % of pos.)                                  2254 (0.9)                    -                  2905 (0.45)
        Hospitalization (count, % of positives)                            260 (0.11)                    -                   292 (0.09)
          Duration, days (med, mean, sd)                                 5, 6.68 (8.46)                  -                4.5, 6.42 (8.08)
548
549
                                                                            37

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
550     Supplementary Table 5. Demographics for severity modeling cohort
551
                                                                          COVID-19
                                                                        Nasopharyngeal
                                                                      Swab Test Positive
                                                                            n = 3,585
       Age
       Median, mean (sd)                                                49, 48.62 (14.68)
       Bins (Counts, %)
       18-30                                                               463 (0.13)
       31-40                                                                725 (0.2)
       41-50                                                               748 (0.21)
       51-60                                                               832 (0.23)
       61-70                                                               555 (0.15)
       71-90                                                               262 (0.07)
       Genetic Sex (counts, %)
       Female                                                             2303 (0.64)
       Male                                                               1282 (0.36)
       Genetic Ancestry Continental Groupings
       Admixed African-European ancestry                                   203 (0.06)
       Admixed Amerindian ancestry                                         397 (0.11)
       European ancestry                                                  2317 (0.65)
       Other ancestry                                                       668 (0.19)
       Pre-existing health conditions (any)                               1666 (0.46)
       BMI (med, mean, sd)                                             28.67, 29.83 (7.03)
       Underweight (count, %)                                                 <100
       Healthy (count, %)                                                      884
       Overweight (count, %)                                                  1128
       Obese (count, %)                                                       1498
       Flu
       Shot (yes)                                                         2293 (0.64)
       Test Dx (yes)                                                       174 (0.05)
       Symptoms (tested pos.)
       General, yes (count, % of pos.)                                     3236 (0.9)
       Hospitalization (count, % of positives)                             391 (0.11)
       Duration, days (med, mean, sd)                                    5, 7.34 (8.73)
552
553
                                                                            38

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
554     Supplementary Table 6. Demographics for susceptibility models with symptoms
                                                                           Susceptibility
                                                                         modeling cohort
                                                                          (with symptom
                                                                                data)
                                                                              n = 4,094
        Age
          Median, mean (sd)                                               58, 55.7 (15.82)
          Bins (Counts, %)
               18-30                                                         293 (0.07)
               31-40                                                         567 (0.14)
               41-50                                                         641 (0.16)
               51-60                                                         795 (0.19)
               61-70                                                         982 (0.24)
               71-90                                                         816 (0.20)
        Genetic Sex (counts, %)
          Female                                                             2744 (0.67)
          Male                                                               1350 (0.33)
        Genetic Ancestry Continental Groupings
          Admixed African-European ancestry                                  172 (0.04)
          Admixed Amerindian ancestry                                        298 (0.07)
          European ancestry                                                  2927 (0.72)
          Other ancestry                                                     666 (0.16)
        Pre-existing health conditions (any)                                 2205 (0.54)
        BMI (med, mean, sd)                                              28.59, 29.8 (6.84)
        Underweight (count, %)                                                  <100
        Healthy (count, %)                                                      1007
        Overweight (count, %)                                                   1335
        Obese (count, %)                                                        1662
        Flu
          Shot (yes)                                                         2935 (0.72)
          Test Dx (yes)                                                      160 (0.04)
        Symptoms (tested pos.)
          General, yes (count, % of pos.)                                    1037 (0.25)
        Hospitalization (count, % of positives)                                 <100
          Duration, days (med, mean, sd)                                   5, 7.53 (10.11)
555
556
                                                                          39

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
557     Supplementary Table 7. Unadjusted risk factor odds ratios for COVID-19 susceptibility
558
        RISK FACTOR                                              ODDS      OR 95% CI       logOR    logOR     P-VALUE      P-VALUE
                                                                 RATIO     (BONFERRONI)             S.E.      (NOMINAL) (BONFERRONI)
                                                                 (OR)
        AGE
        Ages 18-29                                                    1.51 (1.26, 1.81)      0.4108   0.0563      3.05E-13        1.28E-11
        Ages 30-49                                                    1.10 (0.97, 1.24)      0.0944   0.0377      1.22E-02        5.14E-01
        Ages 50-64                                                    1.00                        0           nan          nan
        Ages 65+                                                      0.68 (0.59, 0.79)     -0.3819   0.0454      0.00E+00       0.00E+00
        GENETIC ANCESTRY
        Admixed African-European                                      1.48 (1.18, 1.85)      0.3925   0.0694      1.57E-08        6.58E-07
        European                                                      1.00                        0           nan          nan
        Admixed Amerindian                                            1.49 (1.26, 1.77)      0.3995   0.0523      2.10E-14        8.82E-13
        Other                                                         1.21 (1.06, 1.38)       0.188     0.041     4.62E-06        1.94E-04
        EXPOSURE
        Any                                                           8.72 (7.42, 10.26)     2.1659   0.0501      0.00E+00       0.00E+00
        Biological relative tested positive                           5.77 (4.99, 6.68)      1.7529     0.045     0.00E+00       0.00E+00
        Directly exposed to someone who tested positive               6.94 (6.02, 7.99)      1.9366   0.0438      0.00E+00       0.00E+00
        Healthcare worker directly exposed                            1.44 (1.26, 1.65)       0.367   0.0408      2.31E-19        9.69E-18
        Household member tested positive                             26.03 (22.26, 30.43)    3.2591   0.0482      0.00E+00       0.00E+00
        HEALTH CONDITIONS
        Asthma                                                        0.81 (0.71, 0.94)     -0.2046   0.0446      4.55E-06        1.91E-04
        COPD (Chronic Obstructive Pulmonary Disease)                  0.58 (0.41, 0.82)     -0.5374   0.1057      3.72E-07        1.56E-05
        Cancer treated in the past year                               0.53 (0.36, 0.80)     -0.6283   0.1237      3.80E-07        1.59E-05
        Cardiovascular disease                                        0.71 (0.56, 0.91)     -0.3383   0.0762      9.12E-06        3.83E-04
        Chronic kidney disease                                        0.54 (0.33, 0.87)     -0.6241     0.148     2.48E-05        1.04E-03
        Diabetes                                                      0.86 (0.71, 1.03)     -0.1547   0.0561      5.79E-03        2.43E-01
        Hypertension                                                  0.78 (0.68, 0.89)     -0.2522   0.0411      8.08E-10        3.40E-08
        Other                                                         0.91 (0.73, 1.13)     -0.0939   0.0675      1.64E-01       1.00E+00
        Other autoimmune disease                                      0.77 (0.65, 0.92)     -0.2571     0.054     1.95E-06        8.20E-05
        Other immunodeficiency disorder                               0.77 (0.53, 1.14)     -0.2552   0.1194      3.25E-02       1.00E+00
        Other lung condition                                          0.59 (0.42, 0.82)     -0.5355   0.1037      2.45E-07        1.03E-05
                                                                              40

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Any                                                         0.69 (0.62, 0.77)     -0.3667   0.0336       0.00E+00        0.00E+00
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          0.99 (0.86, 1.13)     -0.0146     0.043      7.35E-01        1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.00 (0.83, 1.19)     -0.0042     0.056      9.41E-01        1.00E+00
        obesity III (BMI >= 40)                                     0.97 (0.80, 1.19)     -0.0255   0.0622       6.81E-01        1.00E+00
        Not obese                                                   1.00                        0           nan           nan
        GENETIC SEX
        Female                                                      1.00                        0           nan           nan
        Male                                                        1.27 (1.14, 1.42)      0.2419   0.0329       1.89E-13
                                                                                                                                  7.95E-12
        SYMPTOMS
        Abdominal pain                                              1.01 (0.77, 1.33)      0.0139   0.0841       8.69E-01        1.00E+00
        Body aches                                                  1.34 (1.06, 1.69)      0.2945   0.0717       4.04E-05         1.70E-03
        Change in taste or smell                                    7.26 (5.54, 9.50)      1.9819   0.0832      1.62E-125       6.81E-124
        Chills                                                      1.37 (1.09, 1.71)      0.3126   0.0697       7.23E-06         3.04E-04
        Cough producing phlegm                                      0.88 (0.69, 1.12)     -0.1318   0.0746       7.74E-02        1.00E+00
        Diarrhea                                                    1.22 (0.96, 1.56)      0.2006   0.0745       7.11E-03         2.99E-01
        Dry cough                                                   1.12 (0.89, 1.40)       0.109   0.0694       1.16E-01        1.00E+00
        Feeling tired or fatigue                                    1.41 (1.05, 1.89)       0.343   0.0901       1.41E-04         5.91E-03
        Fever                                                       1.60 (1.28, 2.01)      0.4715   0.0701       1.74E-11         7.30E-10
        Headache                                                    1.12 (0.88, 1.41)      0.1098   0.0728       1.32E-01        1.00E+00
        Nasal congestion                                            0.74 (0.59, 0.92)     -0.3072   0.0696       1.01E-05         4.24E-04
        Nausea or vomiting                                          0.99 (0.75, 1.32)     -0.0055   0.0867       9.50E-01        1.00E+00
        Runny nose                                                  0.59 (0.47, 0.75)     -0.5245   0.0725       4.49E-13         1.89E-11
        Shortness of breath                                         1.14 (0.91, 1.44)      0.1343   0.0705       5.67E-02        1.00E+00
        Sore throat                                                 0.49 (0.39, 0.62)     -0.7052   0.0717       8.10E-23        0.00E+00
559
560     Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants
561     reporting a test result (positive or negative) based on the self-reported response to the following
562     question: â€œHave you been swab tested for COVID-19, commonly referred to as coronavirus?â€
563     The following groups served as reference populations for the odds ratio calculations: European
564     genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese
565     (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
566     symptomatic customers only (Methods).
                                                                            41

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
567     Supplementary Table 8. Risk factors odds ratios for COVID-19 susceptibility, adjusted for
568     exposure questions
569
        RISK FACTOR                                      ODDS OR 95% CI           logOR    logOR     P-VALUE         P-VALUE
                                                         RATIO (BONFERRONI)                S.E.      (NOMINAL)       (BONFERRONI)
                                                         (OR)
        AGE
        Ages 18-29                                           1.27 (1.02, 1.57)      0.2364    0.0670        4.22E-04              1.77E-02
        Ages 30-49                                           0.95 (0.82, 1.10)     -0.0535    0.0451        2.36E-01             1.00E+00
        Ages 50-64                                           1.00                   0.0000           nan             nan
        Ages 65+                                             0.99 (0.81, 1.21)     -0.0084    0.0610        8.90E-01             1.00E+00
        GENETIC ANCESTRY
        Admixed African-European                             1.23 (0.94, 1.62)      0.2084    0.0848        1.40E-02              5.89E-01
        European                                             1.00                   0.0000           nan             nan
        Admixed Amerindian                                   1.32 (1.08, 1.62)      0.2810    0.0621        6.13E-06              2.57E-04
        Other                                                1.10 (0.93, 1.29)      0.0923    0.0504        6.73E-02             1.00E+00
        EXPOSURE
        Any                                                  8.72 (7.42, 10.26)     2.1659    0.0501        0.00E+00             0.00E+00
        Biological relative tested positive                  5.77 (4.99, 6.68)      1.7529    0.0450        0.00E+00             0.00E+00
        Directly exposed to someone who tested               6.94 (6.02, 7.99)      1.9366    0.0438        0.00E+00             0.00E+00
        positive
        Healthcare worker directly exposed                   1.44 (1.26, 1.65)      0.3670    0.0408        2.31E-19              9.69E-18
        Household member tested positive                    26.03 (22.26, 30.43)    3.2591    0.0482        0.00E+00             0.00E+00
        HEALTH CONDITIONS
        Asthma                                               0.78 (0.66, 0.93)     -0.2450    0.0519        2.37E-06              9.95E-05
        COPD (Chronic Obstructive Pulmonary                  0.85 (0.57, 1.29)     -0.1571    0.1276        2.18E-01             1.00E+00
        Disease)
        Cancer treated in the past year                      0.83 (0.51, 1.34)     -0.1884    0.1480        2.03E-01             1.00E+00
        Cardiovascular disease                               0.96 (0.71, 1.29)     -0.0436    0.0920        6.36E-01             1.00E+00
        Chronic kidney disease                               0.77 (0.43, 1.37)     -0.2656    0.1784        1.37E-01             1.00E+00
        Diabetes                                             1.09 (0.88, 1.35)      0.0886    0.0657        1.78E-01             1.00E+00
        Hypertension                                         0.90 (0.77, 1.05)     -0.1034    0.0479        3.08E-02             1.00E+00
        Other                                                0.97 (0.75, 1.25)     -0.0293    0.0788        7.11E-01             1.00E+00
        Other autoimmune disease                             0.82 (0.67, 1.00)     -0.2042    0.0628        1.15E-03              4.85E-02
        Other immunodeficiency disorder                      0.69 (0.43, 1.11)     -0.3735    0.1482        1.18E-02              4.94E-01
                                                                               42

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                               0.66 (0.44, 0.99)     -0.4166    0.1242        7.99E-04                3.36E-02
        Any                                                0.80 (0.70, 0.91)     -0.2243    0.0391        9.55E-09                4.01E-07
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                 0.99 (0.84, 1.17)     -0.0079    0.0500        8.75E-01               1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                1.04 (0.84, 1.28)      0.0348    0.0647        5.90E-01               1.00E+00
        obesity III (BMI >= 40)                            0.99 (0.79, 1.26)     -0.0056    0.0719        9.38E-01               1.00E+00
        Not obese                                          1.00                   0.0000           nan             nan
        GENETIC SEX
        Female                                             1.00                   0.0000           nan             nan
        Male                                               1.35 (1.18, 1.54)      0.2989    0.0408        2.46E-13                1.04E-11
        SYMPTOMS
        Abdominal pain                                     0.96 (0.68, 1.38)     -0.0364    0.1100        7.41E-01               1.00E+00
        Body aches                                         1.27 (0.94, 1.73)      0.2429    0.0934        9.31E-03                3.91E-01
        Change in taste or smell                           6.43 (4.59, 9.00)      1.8607    0.1039        1.18E-71                4.94E-70
        Chills                                             1.36 (1.01, 1.82)      0.3073    0.0908        7.11E-04                2.99E-02
        Cough producing phlegm                             0.89 (0.64, 1.22)     -0.1208    0.0981        2.18E-01               1.00E+00
        Diarrhea                                           1.13 (0.83, 1.55)      0.1258    0.0963        1.92E-01               1.00E+00
        Dry cough                                          1.02 (0.76, 1.37)      0.0243    0.0906        7.88E-01               1.00E+00
        Feeling tired or fatigue                           1.27 (0.87, 1.86)      0.2389    0.1181        4.31E-02               1.00E+00
        Fever                                              1.53 (1.14, 2.06)      0.4276    0.0911        2.67E-06                1.12E-04
        Headache                                           1.01 (0.74, 1.37)      0.0092    0.0951        9.23E-01               1.00E+00
        Nasal congestion                                   0.69 (0.51, 0.92)     -0.3766    0.0909        3.45E-05                1.45E-03
        Nausea or vomiting                                 0.92 (0.64, 1.33)     -0.0808    0.1122        4.71E-01               1.00E+00
        Runny nose                                         0.56 (0.41, 0.76)     -0.5841    0.0954        9.02E-10                3.79E-08
        Shortness of breath                                1.26 (0.93, 1.70)      0.2286    0.0926        1.35E-02                5.68E-01
        Sore throat                                        0.46 (0.34, 0.63)     -0.7711    0.0940        2.22E-16                9.33E-15
570
571     Adjusted odds ratios for a positive COVID-19 test were calculated among survey participants
572     reporting a test result (positive or negative) based on the self-reported response to the following
573     question: â€œHave you been swab tested for COVID-19, commonly referred to as coronavirus?â€
574     The following groups served as reference populations for the odds ratio calculations: European
575     genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese
576     (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
                                                                             43

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
577     symptomatic customers only (Methods). Here, odds ratios were adjusted for four known
578     exposures (Y/N if any).
579
                                                                          44

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
580     Supplementary Table 9. Risk factor odds ratios for COVID-19 susceptibility, adjusted for
581     exposure, age, and sex
582
        RISK FACTOR                                     ODDS      OR 95% CI       logOR      logOR        P-VALUE       P-VALUE
                                                        RATIO     (BONFERRONI)               S.E.         (NOMINAL)     (BONFERRONI)
                                                        (OR)
        AGE
        Ages 18-29                                           1.28 (1.03, 1.59)       0.2448       0.0672       2.72E-04           1.14E-02
        Ages 30-49                                           0.94 (0.81, 1.09)      -0.0583       0.0453       1.97E-01          1.00E+00
        Ages 50-64                                           1.00                    0.0000               nan           nan
        Ages 65+                                             0.96 (0.79, 1.18)      -0.0372       0.0613       5.44E-01          1.00E+00
        GENETIC ANCESTRY
        Admixed African-European                             1.23 (0.94, 1.62)       0.2091       0.0852       1.42E-02           5.95E-01
        European                                             1.00                    0.0000               nan           nan
        Admixed Amerindian                                   1.27 (1.04, 1.57)       0.2417       0.0636       1.46E-04           6.11E-03
        Other                                                1.09 (0.92, 1.29)       0.0863       0.0509       8.98E-02          1.00E+00
        EXPOSURE
        Any                                                  8.63 (7.31, 10.19)      2.1555       0.0512      0.00E+00           0.00E+00
        Biological relative tested positive                  5.68 (4.90, 6.58)       1.7372       0.0455      0.00E+00           0.00E+00
        Directly exposed to someone who tested               6.71 (5.80, 7.76)       1.9034       0.0451      0.00E+00           0.00E+00
        positive
        Healthcare worker directly exposed                   1.33 (1.16, 1.52)       0.2823       0.0420       1.75E-11           7.34E-10
        Household member tested positive                    25.09 (21.44, 29.36)     3.2224       0.0485      0.00E+00           0.00E+00
        HEALTH CONDITIONS
        Asthma                                               0.82 (0.69, 0.97)      -0.2045       0.0524       9.47E-05           3.98E-03
        COPD (Chronic Obstructive Pulmonary                  0.88 (0.58, 1.34)      -0.1281       0.1290       3.21E-01          1.00E+00
        Disease)
        Cancer treated in the past year                      0.83 (0.51, 1.34)      -0.1877       0.1488       2.07E-01          1.00E+00
        Cardiovascular disease                               0.94 (0.69, 1.28)      -0.0598       0.0944       5.27E-01          1.00E+00
        Chronic kidney disease                               0.78 (0.44, 1.40)      -0.2475       0.1791       1.67E-01          1.00E+00
        Diabetes                                             1.10 (0.88, 1.36)       0.0922       0.0673       1.71E-01          1.00E+00
        Hypertension                                         0.90 (0.76, 1.05)      -0.1097       0.0499       2.80E-02          1.00E+00
        Other                                                0.99 (0.77, 1.28)      -0.0080       0.0790       9.20E-01          1.00E+00
        Other autoimmune disease                             0.87 (0.71, 1.07)      -0.1382       0.0636       2.97E-02          1.00E+00
        Other immunodeficiency disorder                      0.69 (0.42, 1.11)      -0.3764       0.1496       1.19E-02           4.99E-01
                                                                               45

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                               0.67 (0.44, 1.00)      -0.4064      0.1248        1.13E-03             4.76E-02
        Any                                                0.81 (0.71, 0.92)      -0.2092      0.0405        2.32E-07             9.76E-06
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                 0.99 (0.84, 1.16)      -0.0113      0.0502        8.23E-01            1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                1.04 (0.84, 1.28)       0.0390      0.0649        5.47E-01            1.00E+00
        obesity III (BMI >= 40)                            1.01 (0.80, 1.28)       0.0097      0.0724        8.94E-01            1.00E+00
        Not obese                                          1.00                    0.0000               nan           nan
        GENETIC SEX
        Female                                             1.00                    0.0000               nan           nan
        Male                                               1.36 (1.19, 1.55)       0.3039      0.0409        1.09E-13             4.57E-12
        SYMPTOMS
        Abdominal pain                                     1.00 (0.70, 1.44)       0.0048      0.1108        9.65E-01            1.00E+00
        Body aches                                         1.29 (0.95, 1.74)       0.2508      0.0941        7.72E-03             3.24E-01
        Change in taste or smell                           6.68 (4.75, 9.39)       1.8991      0.1052        6.77E-73             2.84E-71
        Chills                                             1.35 (1.01, 1.82)       0.3014      0.0912        9.56E-04             4.02E-02
        Cough producing phlegm                             0.90 (0.65, 1.23)      -0.1098      0.0986        2.65E-01            1.00E+00
        Diarrhea                                           1.16 (0.85, 1.59)       0.1522      0.0970        1.17E-01            1.00E+00
        Dry cough                                          1.05 (0.78, 1.40)       0.0442      0.0912        6.28E-01            1.00E+00
        Feeling tired or fatigue                           1.35 (0.92, 2.00)       0.3029      0.1202        1.17E-02             4.91E-01
        Fever                                              1.52 (1.13, 2.05)       0.4189      0.0916        4.76E-06             2.00E-04
        Headache                                           1.02 (0.74, 1.40)       0.0218      0.0977        8.24E-01            1.00E+00
        Nasal congestion                                   0.69 (0.52, 0.93)      -0.3651      0.0918        6.93E-05             2.91E-03
        Nausea or vomiting                                 0.96 (0.67, 1.38)      -0.0401      0.1128        7.22E-01            1.00E+00
        Runny nose                                         0.57 (0.42, 0.77)      -0.5690      0.0958        2.83E-09             1.19E-07
        Shortness of breath                                1.30 (0.96, 1.76)       0.2607      0.0934        5.22E-03             2.19E-01
        Sore throat                                        0.47 (0.34, 0.64)      -0.7609      0.0951        1.33E-15             5.60E-14
583
584     Adjusted odds ratios for a positive COVID-19 test were calculated among survey participants
585     reporting a test result (positive or negative) based on the self-reported response to the following
586     question: â€œHave you been swab tested for COVID-19, commonly referred to as coronavirus?â€
587     The following groups served as reference populations for the odds ratio calculations: European
588     genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese
589     (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
                                                                             46

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
590     symptomatic customers only (Methods). Here, odds ratios were adjusted for four known
591     exposures (Y/N if any), age, and genetic sex (Supplementary Table 2 and Methods).
592
593
                                                                          47

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
594     Supplementary Table 10. Unadjusted risk factor odds ratios for a known â€œdirectâ€ COVID-
595     19 exposure
596
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE       P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    1.80 (1.54, 2.12)      0.5896   0.0519       6.64E-30        1.66E-28
        Ages 30-49                                                    1.45 (1.31, 1.60)      0.3725   0.0325       2.00E-30        5.00E-29
        Ages 50-64                                                    1.00                   0.0000           nan           nan
        Ages 65+                                                      0.32 (0.28, 0.37)     -1.1427   0.0437       0.00E+00        0.00E+00
        GENETIC ANCESTRY
        Admixed African-European                                      1.49 (1.23, 1.82)      0.4012   0.0639       3.32E-10        8.31E-09
        European                                                      1.00                   0.0000           nan           nan
        Admixed Amerindian                                            1.40 (1.21, 1.62)      0.3384   0.0476       1.13E-12        2.82E-11
        Other                                                         1.17 (1.05, 1.31)      0.1584   0.0365       1.47E-05        3.67E-04
        EXPOSURE
        Biological relative tested positive                           4.43 (3.79, 5.18)      1.4888   0.0503      1.39E-192       3.48E-191
        Healthcare worker directly exposed                           11.53 (10.16, 13.08)    2.4450   0.0408       0.00E+00        0.00E+00
        Household member tested positive                             22.53 (17.88, 28.38)    3.1148   0.0747       0.00E+00        0.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.02 (0.92, 1.14)      0.0216   0.0353       5.40E-01        1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  0.44 (0.33, 0.57)     -0.8297   0.0875       0.00E+00        0.00E+00
        Cancer treated in the past year                               0.36 (0.26, 0.49)     -1.0310   0.1012       0.00E+00        0.00E+00
        Cardiovascular disease                                        0.50 (0.41, 0.61)     -0.6880   0.0647       0.00E+00        0.00E+00
        Chronic kidney disease                                        0.39 (0.27, 0.57)     -0.9295   0.1182       3.77E-15        9.44E-14
        Diabetes                                                      0.63 (0.54, 0.73)     -0.4656   0.0473       0.00E+00        0.00E+00
        Hypertension                                                  0.73 (0.66, 0.81)     -0.3181   0.0332       0.00E+00        0.00E+00
        Other                                                         0.99 (0.84, 1.18)     -0.0080   0.0556       8.86E-01        1.00E+00
        Other autoimmune disease                                      0.87 (0.76, 0.99)     -0.1421   0.0424       8.06E-04        2.02E-02
        Other immunodeficiency disorder                               0.87 (0.65, 1.17)     -0.1389   0.0953       1.45E-01        1.00E+00
        Other lung condition                                          0.62 (0.48, 0.78)     -0.4859   0.0778       4.22E-10        1.05E-08
        Any                                                           0.71 (0.65, 0.78)     -0.3393   0.0276       0.00E+00        0.00E+00
                                                                              48

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.03 (0.93, 1.15)      0.0338   0.0350      3.35E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.03 (0.90, 1.19)      0.0343   0.0456      4.52E-01         1.00E+00
        obesity III (BMI >= 40)                                     1.10 (0.94, 1.28)      0.0927   0.0499      6.31E-02         1.00E+00
        Not obese                                                   1.00                   0.0000           nan          nan
        GENETIC SEX
        Female                                                      1.00                   0.0000           nan          nan
        Male                                                        0.96 (0.87, 1.05)     -0.0443   0.0295      1.33E-01
                                                                                                                                 1.00E+00
597
598     Unadjusted odds ratios for a known â€œdirectâ€ exposure to COVID-19 were calculated based on
599     the self-reported response to the following question: â€œHave you been directly exposed to
600     someone who has tested positive for COVID-19?â€ The following groups served as reference
601     populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
602     50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity).
603
604
605
606
607
608
609
610
611
612
613
614
615
616
                                                                            49

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
617     Supplementary Table 11. Unadjusted risk factor odds ratios for a household case(s) of
618     COVID-19
619
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    1.44 (1.15, 1.79)      0.3623   0.0715      4.01E-07        1.00E-05
        Ages 30-49                                                    0.98 (0.84, 1.14)     -0.0204   0.0488      6.76E-01       1.00E+00
        Ages 50-64                                                    1.00                   0.0000           nan          nan
        Ages 65+                                                      0.50 (0.41, 0.61)     -0.6882   0.0641      0.00E+00       0.00E+00
        GENETIC ANCESTRY
        Admixed African-European                                      1.35 (1.00, 1.81)      0.2971   0.0954      1.84E-03        4.60E-02
        European                                                      1.00                   0.0000           nan          nan
        Admixed Amerindian                                            1.95 (1.60, 2.37)      0.6686   0.0634      5.56E-26        1.39E-24
        Other                                                         1.23 (1.04, 1.47)      0.2107   0.0557      1.56E-04        3.90E-03
        EXPOSURE
        Biological relative tested positive                          14.32 (12.30, 16.67)    2.6615   0.0491      0.00E+00       0.00E+00
        Directly exposed to someone who tested positive              22.53 (17.88, 28.38)    3.1148   0.0747      0.00E+00       0.00E+00
        Healthcare worker directly exposed                            1.11 (0.94, 1.32)      0.1073   0.0540      4.71E-02       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        0.91 (0.77, 1.07)     -0.0975   0.0549      7.59E-02       1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  0.58 (0.38, 0.89)     -0.5405   0.1363      7.31E-05        1.83E-03
        Cancer treated in the past year                               0.44 (0.26, 0.75)     -0.8217   0.1735      2.19E-06        5.48E-05
        Cardiovascular disease                                        0.68 (0.50, 0.93)     -0.3795   0.0988      1.23E-04        3.07E-03
        Chronic kidney disease                                        0.53 (0.30, 0.97)     -0.6255   0.1911      1.06E-03        2.66E-02
        Diabetes                                                      0.89 (0.72, 1.10)     -0.1187   0.0701      9.02E-02       1.00E+00
        Hypertension                                                  0.80 (0.69, 0.94)     -0.2182   0.0516      2.31E-05        5.77E-04
        Other                                                         0.93 (0.72, 1.21)     -0.0673   0.0845      4.26E-01       1.00E+00
        Other autoimmune disease                                      0.85 (0.69, 1.04)     -0.1684   0.0667      1.16E-02        2.90E-01
        Other immunodeficiency disorder                               0.87 (0.56, 1.37)     -0.1357   0.1453      3.50E-01       1.00E+00
        Other lung condition                                          0.63 (0.42, 0.94)     -0.4620   0.1292      3.48E-04        8.70E-03
        Any                                                           0.74 (0.65, 0.84)     -0.3047   0.0423      5.80E-13        1.45E-11
                                                                              50

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.05 (0.89, 1.23)      0.0460   0.0533      3.88E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.01 (0.81, 1.25)      0.0064   0.0704      9.28E-01         1.00E+00
        obesity III (BMI >= 40)                                     1.04 (0.82, 1.32)      0.0374   0.0769      6.27E-01         1.00E+00
        Not obese                                                   1.00                   0.0000           nan          nan
        GENETIC SEX
        Female                                                      1.00                   0.0000           nan          nan
        Male                                                        1.18 (1.03, 1.36)      0.1688   0.0438      1.16E-04
                                                                                                                                  2.89E-03
620
621     Unadjusted odds ratios for a household case(s) of COVID-19 were calculated based on the self-
622     reported response to the following question: â€œHas someone in your household tested positive for
623     COVID-19?â€ The following groups served as reference populations for the odds ratio
624     calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic
625     Sex), and Not Obese (BMI < 30, Obesity).
626
627
628
629
630
631
632
633
634
635
636
637
638
                                                                            51

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
639     Supplementary Table 12. Unadjusted risk factor odds ratios for a COVID-19 case(s)
640     amongst close biological relatives (parent, grandparent, child, or sibling)
641
        RISK FACTOR                                              ODDS OR 95% CI            logOR    logOR    P-VALUE     P-VALUE
                                                                 RATIO (BONFERRONI)                 S.E.     (NOMINA     (BONFERRONI)
                                                                 (OR)                                        L)
        AGE
        Ages 18-29                                                   1.48 (1.18, 1.86)       0.3934   0.0730    7.16E-08          1.79E-06
        Ages 30-49                                                   1.02 (0.88, 1.19)       0.0222   0.0502    6.59E-01         1.00E+00
        Ages 50-64                                                   1.00                    0.0000          nan         nan
        Ages 65+                                                     0.70 (0.58, 0.85)      -0.3523   0.0605    5.90E-09          1.47E-07
        GENETIC ANCESTRY
        Admixed African-European                                     1.69 (1.28, 2.22)       0.5221   0.0896    5.62E-09          1.41E-07
        European                                                     1.00                    0.0000          nan         nan
        Admixed Amerindian                                           2.08 (1.71, 2.53)       0.7333   0.0634    5.85E-31          1.46E-29
        Other                                                        1.42 (1.20, 1.68)       0.3472   0.0547    2.14E-10          5.34E-09
        EXPOSURE
        Directly exposed to someone who tested positive              4.43 (3.79, 5.18)       1.4888   0.0503   1.39E-192        3.48E-191
        Healthcare worker directly exposed                           1.04 (0.87, 1.23)       0.0384   0.0558    4.91E-01         1.00E+00
        Household member tested positive                            14.32 (12.30, 16.67)     2.6615   0.0491    0.00E+00         0.00E+00
        HEALTH CONDITIONS
        Asthma                                                       0.98 (0.82, 1.16)      -0.0245   0.0547    6.54E-01         1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                 0.68 (0.46, 1.02)      -0.3791   0.1293    3.37E-03          8.42E-02
        Cancer treated in the past year                              0.60 (0.37, 0.97)      -0.5105   0.1542    9.33E-04          2.33E-02
        Cardiovascular disease                                       0.77 (0.57, 1.04)      -0.2600   0.0959    6.72E-03          1.68E-01
        Chronic kidney disease                                       0.52 (0.28, 0.95)      -0.6619   0.1977    8.12E-04          2.03E-02
        Diabetes                                                     1.04 (0.84, 1.28)       0.0368   0.0677    5.86E-01         1.00E+00
        Hypertension                                                 0.88 (0.75, 1.03)      -0.1281   0.0513    1.25E-02          3.12E-01
        Other                                                        1.03 (0.80, 1.33)       0.0297   0.0829    7.20E-01         1.00E+00
        Other autoimmune disease                                     0.90 (0.73, 1.10)      -0.1057   0.0663    1.11E-01         1.00E+00
        Other immunodeficiency disorder                              0.99 (0.65, 1.53)      -0.0065   0.1394    9.63E-01         1.00E+00
        Other lung condition                                         0.96 (0.69, 1.36)      -0.0368   0.1104    7.39E-01         1.00E+00
        Any                                                          0.85 (0.74, 0.97)      -0.1668   0.0429    1.02E-04          2.55E-03
                                                                           52

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                           1.03 (0.87, 1.22)      0.0327    0.0541    5.45E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                          0.88 (0.70, 1.11)     -0.1292    0.0748    8.41E-02         1.00E+00
        obesity III (BMI >= 40)                                      1.10 (0.87, 1.39)      0.0945    0.0761    2.14E-01         1.00E+00
        Not obese                                                    1.00                   0.0000           nan         nan
        GENETIC SEX
        Female                                                       1.00                   0.0000           nan         nan
        Male                                                         0.87 (0.75, 1.00)     -0.1404    0.0462    2.39E-03
                                                                                                                                  5.99E-02
642
643     Unadjusted odds ratios for a case(s) of COVID-19 among close biological relatives (grandparent,
644     parent, child, or sibling) were calculated based on the self-reported response to the following
645     question: â€œHave any of your biological relatives tested positive for COVID-19? Select all that
646     apply.â€ The following groups served as reference populations for the odds ratio calculations:
647     European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and
648     Not Obese (BMI < 30, Obesity).
649
650
651
652
653
654
655
656
657
658
659
660
661
                                                                           53

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
662     Supplementary Table 13. Unadjusted risk factor odds ratios for COVID-19 hospitalization
663
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.42 (0.21, 0.83)     -0.8793   0.2143      4.06E-05        1.71E-03
        Ages 30-49                                                    0.54 (0.36, 0.81)     -0.6143   0.1246      8.24E-07        3.46E-05
        Ages 50-64                                                    1.00                   0.0000           nan          nan
        Ages 65+                                                      1.70 (1.13, 2.56)      0.5325   0.1263      2.49E-05        1.05E-03
        GENETIC ANCESTRY
        Admixed African-European                                      1.44 (0.78, 2.65)      0.3625   0.1884      5.43E-02       1.00E+00
        European                                                      1.00                   0.0000           nan          nan
        Admixed Amerindian                                            0.77 (0.44, 1.36)     -0.2579   0.1745      1.39E-01       1.00E+00
        Other                                                         0.91 (0.59, 1.40)     -0.0964   0.1335      4.70E-01       1.00E+00
        EXPOSURE
        Any                                                           0.74 (0.46, 1.19)     -0.3048   0.1483      3.98E-02       1.00E+00
        Biological relative tested positive                           1.17 (0.81, 1.69)      0.1550   0.1136      1.73E-01       1.00E+00
        Directly exposed to someone who tested positive               0.63 (0.42, 0.96)     -0.4595   0.1279      3.28E-04        1.38E-02
        Healthcare worker directly exposed                            0.53 (0.34, 0.84)     -0.6317   0.1423      9.09E-06        3.82E-04
        Household member tested positive                              0.91 (0.65, 1.27)     -0.0971   0.1033      3.47E-01       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.42 (0.95, 2.13)      0.3525   0.1249      4.77E-03        2.00E-01
        COPD (Chronic Obstructive Pulmonary Disease)                  3.48 (1.65, 7.32)      1.2469   0.2296      5.64E-08        2.37E-06
        Cancer treated in the past year                               3.13 (1.29, 7.57)      1.1396   0.2730      2.99E-05        1.26E-03
        Cardiovascular disease                                        2.82 (1.61, 4.96)      1.0374   0.1740      2.50E-09        1.05E-07
        Chronic kidney disease                                        8.74 (3.44, 22.21)     2.1684   0.2876      4.71E-14        1.98E-12
        Diabetes                                                      3.03 (1.98, 4.63)      1.1085   0.1311      2.78E-17        1.17E-15
        Hypertension                                                  2.01 (1.41, 2.88)      0.7002   0.1105      2.37E-10        9.96E-09
        Other                                                         1.65 (0.93, 2.93)      0.5038   0.1767      4.35E-03        1.83E-01
        Other autoimmune disease                                      1.32 (0.81, 2.17)      0.2811   0.1523      6.49E-02       1.00E+00
        Other immunodeficiency disorder                               1.98 (0.77, 5.09)      0.6826   0.2915      1.92E-02        8.05E-01
        Other lung condition                                          2.84 (1.32, 6.10)      1.0423   0.2364      1.04E-05        4.35E-04
                                                                              54

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Any                                                         2.70 (1.90, 3.83)      0.9919   0.1081      4.43E-20          1.86E-18
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.41 (0.94, 2.12)      0.3418   0.1258      6.61E-03          2.78E-01
        obesity II (BMI >= 35 and BMI < 40)                         1.21 (0.70, 2.09)      0.1883   0.1693      2.66E-01         1.00E+00
        obesity III (BMI >= 40)                                     1.62 (0.93, 2.83)      0.4820   0.1719      5.04E-03          2.12E-01
        Not obese                                                   1.00                   0.0000           nan          nan
        GENETIC SEX
        Female                                                      1.00                   0.0000           nan          nan
        Male                                                        1.27 (0.92, 1.77)      0.2418   0.1015      1.72E-02
                                                                                                                                  7.22E-01
        SYMPTOMS
        Abdominal pain                                              1.76 (1.23, 2.52)      0.5638   0.1112      3.92E-07          1.65E-05
        Body aches                                                  1.39 (0.96, 2.02)      0.3309   0.1142      3.75E-03          1.57E-01
        Change in taste or smell                                    0.77 (0.55, 1.07)     -0.2657   0.1039      1.05E-02          4.42E-01
        Chills                                                      1.82 (1.29, 2.57)      0.5991   0.1061      1.65E-08          6.92E-07
        Cough producing phlegm                                      1.56 (1.11, 2.20)      0.4474   0.1054      2.19E-05          9.18E-04
        Diarrhea                                                    2.12 (1.52, 2.95)      0.7521   0.1021      1.75E-13          7.35E-12
        Dry cough                                                   2.59 (1.81, 3.71)      0.9528   0.1104      6.26E-18          2.63E-16
        Feeling tired or fatigue                                    2.54 (1.35, 4.78)      0.9335   0.1949      1.68E-06          7.04E-05
        Fever                                                       3.33 (2.26, 4.90)      1.2032   0.1192      5.93E-24          2.49E-22
        Headache                                                    0.89 (0.63, 1.26)     -0.1125   0.1063      2.90E-01         1.00E+00
        Nasal congestion                                            0.94 (0.67, 1.31)     -0.0610   0.1030      5.54E-01         1.00E+00
        Nausea or vomiting                                          2.26 (1.58, 3.23)      0.8156   0.1104      1.52E-13          6.39E-12
        Runny nose                                                  1.09 (0.76, 1.56)      0.0831   0.1118      4.57E-01         1.00E+00
        Shortness of breath                                         7.52 (4.92, 11.49)     2.0172   0.1309      1.48E-53          6.21E-52
        Sore throat                                                 1.04 (0.72, 1.50)      0.0386   0.1127      7.32E-01         1.00E+00
664
665     Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among
666     those reporting a positive COVID-19 test result. The following groups served as reference
667     populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
668     50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms
669     odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).
670
                                                                            55

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
671     Supplementary Table 14. Risk factor odds ratios for COVID-19 hospitalization, adjusted
672     for health conditions, obesity, age, and sex
673
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.56 (0.26, 1.20)     -0.5815   0.2359      1.37E-02        5.75E-01
        Ages 30-49                                                    0.60 (0.39, 0.92)     -0.5110   0.1333      1.26E-04        5.28E-03
        Ages 50-64                                                    1.00                   0.0000           nan          nan
        Ages 65+                                                      1.60 (1.02, 2.51)      0.4713   0.1381      6.43E-04        2.70E-02
        GENETIC ANCESTRY
        Admixed African-European                                      1.57 (0.81, 3.03)      0.4513   0.2026      2.59E-02       1.00E+00
        European                                                      1.00                   0.0000           nan          nan
        Admixed Amerindian                                            1.11 (0.59, 2.07)      0.1035   0.1922      5.90E-01       1.00E+00
        Other                                                         0.95 (0.59, 1.54)     -0.0493   0.1490      7.41E-01       1.00E+00
        EXPOSURE
        Any                                                           0.81 (0.48, 1.39)     -0.2060   0.1653      2.13E-01       1.00E+00
        Biological relative tested positive                           1.16 (0.78, 1.74)      0.1498   0.1248      2.30E-01       1.00E+00
        Directly exposed to someone who tested positive               0.68 (0.43, 1.07)     -0.3870   0.1397      5.61E-03        2.36E-01
        Healthcare worker directly exposed                            0.63 (0.38, 1.04)     -0.4685   0.1567      2.79E-03        1.17E-01
        Household member tested positive                              0.88 (0.62, 1.26)     -0.1245   0.1109      2.62E-01       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.42 (0.92, 2.20)      0.3537   0.1343      8.42E-03        3.54E-01
        COPD (Chronic Obstructive Pulmonary Disease)                  2.25 (0.99, 5.14)      0.8123   0.2542      1.40E-03        5.87E-02
        Cancer treated in the past year                               1.90 (0.72, 5.04)      0.6422   0.3012      3.30E-02       1.00E+00
        Cardiovascular disease                                        1.67 (0.90, 3.11)      0.5139   0.1914      7.24E-03        3.04E-01
        Chronic kidney disease                                        5.62 (2.10, 15.03)     1.7267   0.3034      1.26E-08        5.30E-07
        Diabetes                                                      2.22 (1.39, 3.55)      0.7988   0.1442      3.06E-08        1.28E-06
        Hypertension                                                  1.32 (0.88, 1.97)      0.2757   0.1239      2.61E-02       1.00E+00
        Other                                                         1.47 (0.80, 2.71)      0.3878   0.1875      3.86E-02       1.00E+00
        Other autoimmune disease                                      1.41 (0.83, 2.40)      0.3461   0.1635      3.42E-02       1.00E+00
        Other immunodeficiency disorder                               1.83 (0.68, 4.93)      0.6032   0.3062      4.88E-02       1.00E+00
                                                                              56

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                                        1.87 (0.83, 4.22)      0.6242   0.2514      1.30E-02          5.47E-01
        Any                                                         2.08 (1.42, 3.04)      0.7333   0.1172      3.93E-10          1.65E-08
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.19 (0.77, 1.82)      0.1707   0.1323      1.97E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.13 (0.64, 2.00)      0.1249   0.1750      4.75E-01         1.00E+00
        obesity III (BMI >= 40)                                     1.59 (0.88, 2.87)      0.4631   0.1821      1.10E-02          4.62E-01
        Not obese                                                   1.00                   0.0000           nan          nan
        GENETIC SEX
        Female                                                      1.00                   0.0000           nan          nan
        Male                                                        1.22 (0.85, 1.74)      0.1960   0.1103      7.57E-02         1.00E+00
        SYMPTOMS
        Abdominal pain                                              1.66 (1.12, 2.46)      0.5086   0.1214      2.81E-05          1.18E-03
        Body aches                                                  1.44 (0.96, 2.15)      0.3646   0.1240      3.27E-03          1.37E-01
        Change in taste or smell                                    0.89 (0.62, 1.29)     -0.1159   0.1139      3.09E-01         1.00E+00
        Chills                                                      1.94 (1.33, 2.82)      0.6609   0.1156      1.07E-08          4.51E-07
        Cough producing phlegm                                      1.41 (0.97, 2.05)      0.3470   0.1150      2.54E-03          1.07E-01
        Diarrhea                                                    2.23 (1.55, 3.20)      0.8014   0.1120      8.21E-13          3.45E-11
        Dry cough                                                   2.49 (1.69, 3.67)      0.9114   0.1196      2.55E-14          1.07E-12
        Feeling tired or fatigue                                    2.81 (1.38, 5.74)      1.0333   0.2203      2.73E-06          1.15E-04
        Fever                                                       3.49 (2.29, 5.34)      1.2510   0.1309      1.24E-21          5.19E-20
        Headache                                                    1.05 (0.72, 1.54)      0.0487   0.1180      6.80E-01         1.00E+00
        Nasal congestion                                            0.93 (0.65, 1.34)     -0.0698   0.1122      5.34E-01         1.00E+00
        Nausea or vomiting                                          2.41 (1.62, 3.59)      0.8801   0.1230      8.38E-13          3.52E-11
        Runny nose                                                  0.93 (0.62, 1.39)     -0.0710   0.1232      5.65E-01         1.00E+00
        Shortness of breath                                         8.20 (5.14, 13.08)     2.1042   0.1440      2.37E-48          9.96E-47
        Sore throat                                                 1.11 (0.75, 1.66)      0.1074   0.1224      3.80E-01         1.00E+00
674
675     Adjusted odds ratios for hospitalization due to COVID-19 infection were calculated among those
676     reporting a positive COVID-19 test result. The following groups served as reference populations
677     for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age),
678     Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios
679     were calculated in a binary fashion among symptomatic customers only (Methods). Here, odds
680     ratios were adjusted for age, sex, comorbitidies (Y/N if any), and obesity (Y/N if BMI > 30,
681     Methods).
682
                                                                            57

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
683     Supplementary Table 15. Unadjusted risk factor odds ratios for progression of COVID-19
684     to a critical case.
685
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.35 (0.13, 0.95)     -1.0599   0.3114      6.64E-04        2.79E-02
        Ages 30-49                                                    0.55 (0.32, 0.94)     -0.5983   0.1652      2.92E-04        1.23E-02
        Ages 50-64                                                       1                        0           nan          nan
        Ages 65+                                                      1.65 (0.97, 2.80)      0.5001   0.1632      2.19E-03        9.18E-02
        GENETIC ANCESTRY
        Admixed African-European                                      2.07 (1.03, 4.17)      0.7269   0.2166      7.91E-04        3.32E-02
        European                                                         1                        0           nan          nan
        Admixed Amerindian                                            0.75 (0.35, 1.62)     -0.2871   0.2377      2.27E-01       1.00E+00
        Other                                                         0.82 (0.45, 1.49)     -0.2044   0.1853      2.70E-01       1.00E+00
        EXPOSURE
        Any                                                           0.77 (0.40, 1.45)     -0.2675   0.1981      1.77E-01       1.00E+00
        Biological relative tested positive                           1.15 (0.70, 1.86)      0.1356   0.1502      3.67E-01       1.00E+00
        Directly exposed to someone who tested positive               0.59 (0.34, 1.01)     -0.5348   0.1691      1.56E-03        6.55E-02
        Healthcare worker directly exposed                            0.53 (0.29, 0.99)     -0.6277   0.1912      1.03E-03        4.31E-02
        Household member tested positive                              1.00 (0.64, 1.55)     -0.0001   0.1353      1.00E+00       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.26 (0.74, 2.17)       0.235   0.1672      1.60E-01       1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  3.76 (1.57, 9.02)      1.3257   0.2696      8.79E-07        3.69E-05
        Cancer treated in the past year                               2.07 (0.60, 7.12)      0.7266   0.3814      5.68E-02       1.00E+00
        Cardiovascular disease                                        2.44 (1.17, 5.05)      0.8906   0.2251      7.60E-05        3.19E-03
        Chronic kidney disease                                        8.00 (2.92, 21.91)     2.0794   0.3109      2.26E-11        9.47E-10
        Diabetes                                                      3.14 (1.85, 5.32)      1.1431   0.1629      2.29E-12        9.61E-11
        Hypertension                                                  2.06 (1.30, 3.27)      0.7214   0.1425      4.15E-07        1.74E-05
        Other                                                         1.07 (0.45, 2.54)      0.0649   0.2674      8.08E-01       1.00E+00
        Other autoimmune disease                                      1.35 (0.71, 2.55)      0.2973   0.1973      1.32E-01       1.00E+00
        Other immunodeficiency disorder                               1.81 (0.53, 6.16)      0.5907   0.3788      1.19E-01       1.00E+00
                                                                              58

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                                        3.29 (1.35, 8.00)      1.1909     0.274     1.39E-05          5.82E-04
        Any                                                         2.85 (1.78, 4.57)      1.0485   0.1452      5.22E-13          2.19E-11
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.31 (0.76, 2.27)      0.2714   0.1696      1.09E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.16 (0.56, 2.43)      0.1525   0.2275      5.03E-01         1.00E+00
        obesity III (BMI >= 40)                                     2.06 (1.05, 4.02)      0.7211   0.2071      4.98E-04          2.09E-02
        Not obese                                                      1                        0           nan          nan
        GENETIC SEX
        Female                                                         1                        0           nan          nan
        Male                                                        1.54 (1.00, 2.37)      0.4342   0.1325      1.05E-03
                                                                                                                                  4.42E-02
        SYMPTOMS
        Abdominal pain                                              1.95 (1.23, 3.08)       0.666   0.1413      2.45E-06          1.03E-04
        Body aches                                                  1.58 (0.95, 2.60)      0.4547   0.1546      3.27E-03          1.37E-01
        Change in taste or smell                                    0.79 (0.51, 1.23)     -0.2319   0.1358      8.79E-02         1.00E+00
        Chills                                                      2.04 (1.28, 3.23)      0.7106   0.1423      5.96E-07          2.50E-05
        Cough producing phlegm                                      1.83 (1.18, 2.84)      0.6063   0.1351      7.24E-06          3.04E-04
        Diarrhea                                                    2.48 (1.61, 3.84)      0.9102   0.1339      1.08E-11          4.53E-10
        Dry cough                                                   2.67 (1.66, 4.31)      0.9836   0.1474      2.49E-11          1.04E-09
        Feeling tired or fatigue                                    2.55 (1.09, 5.97)      0.9344   0.2628      3.77E-04          1.58E-02
        Fever                                                       3.52 (2.08, 5.96)      1.2595   0.1622      8.00E-15          3.36E-13
        Headache                                                    0.97 (0.61, 1.52)     -0.0356   0.1402      8.00E-01         1.00E+00
        Nasal congestion                                            1.06 (0.69, 1.64)      0.0592   0.1337      6.58E-01         1.00E+00
        Nausea or vomiting                                          2.27 (1.44, 3.60)      0.8217   0.1415      6.30E-09          2.64E-07
        Runny nose                                                  1.31 (0.83, 2.07)      0.2696   0.1415      5.68E-02         1.00E+00
        Shortness of breath                                        11.55 (5.91, 22.59)     2.4466   0.2069      2.93E-32          1.23E-30
        Sore throat                                                 1.45 (0.92, 2.29)       0.374   0.1396      7.40E-03          3.11E-01
686
687     Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening
688     illness were calculated among those reporting a positive COVID-19 test result. The following
689     groups served as reference populations for the odds ratio calculations: European genetic ancestry
690     (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30,
691     Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
692     symptomatic customers only (Methods).
693
                                                                            59

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
694     Supplementary Table 16. Risk factor odds ratios for progression of COVID-19 to a critical
695     case, adjusted for health conditions, obesity, age, and sex.
696
        RISK FACTOR                                               ODDS OR 95% CI           logOR     logOR    P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                 S.E.     (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.46 (0.15, 1.45)     -0.7675    0.3506     2.86E-02       1.00E+00
        Ages 30-49                                                    0.67 (0.38, 1.17)     -0.4033    0.1735     2.01E-02        8.45E-01
        Ages 50-64                                                       1                         0          nan          nan
        Ages 65+                                                      1.51 (0.85, 2.69)         0.41   0.1785     2.16E-02        9.07E-01
        GENETIC ANCESTRY
        Admixed African-European                                      2.34 (1.11, 4.95)      0.8516    0.2308     2.25E-04        9.43E-03
        European                                                         1                         0          nan          nan
        Admixed Amerindian                                            1.12 (0.49, 2.56)      0.1145    0.2548     6.53E-01       1.00E+00
        Other                                                         0.85 (0.44, 1.65)      -0.164     0.206     4.26E-01       1.00E+00
        EXPOSURE
        Any                                                           0.83 (0.41, 1.67)     -0.1862    0.2163     3.89E-01       1.00E+00
        Biological relative tested positive                           1.23 (0.73, 2.08)      0.2104    0.1609     1.91E-01       1.00E+00
        Directly exposed to someone who tested positive               0.62 (0.34, 1.13)     -0.4747     0.183     9.49E-03        3.98E-01
        Healthcare worker directly exposed                            0.62 (0.31, 1.24)     -0.4703    0.2116     2.63E-02       1.00E+00
        Household member tested positive                              1.01 (0.63, 1.60)      0.0068    0.1434     9.62E-01       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.24 (0.69, 2.22)      0.2124    0.1806     2.40E-01       1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  2.39 (0.90, 6.36)      0.8704     0.302     3.95E-03        1.66E-01
        Cancer treated in the past year                               1.08 (0.26, 4.55)      0.0784    0.4429     8.59E-01       1.00E+00
        Cardiovascular disease                                        1.42 (0.64, 3.15)      0.3485    0.2469     1.58E-01       1.00E+00
        Chronic kidney disease                                        4.88 (1.67, 14.30)      1.586    0.3314     1.70E-06        7.13E-05
        Diabetes                                                      2.16 (1.20, 3.89)      0.7699    0.1816     2.23E-05        9.38E-04
        Hypertension                                                  1.34 (0.80, 2.24)      0.2903    0.1599     6.95E-02       1.00E+00
        Other                                                         1.19 (0.49, 2.88)      0.1765    0.2714     5.16E-01       1.00E+00
        Other autoimmune disease                                      1.55 (0.78, 3.06)      0.4368    0.2105     3.80E-02       1.00E+00
        Other immunodeficiency disorder                               1.82 (0.52, 6.31)      0.5962    0.3844     1.21E-01       1.00E+00
                                                                              60

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                                        2.09 (0.80, 5.47)      0.7376   0.2965      1.29E-02          5.40E-01
        Any                                                         2.22 (1.33, 3.69)      0.7959     0.157     4.00E-07          1.68E-05
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.09 (0.62, 1.93)      0.0882   0.1761      6.17E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.06 (0.50, 2.26)      0.0605   0.2334      7.96E-01         1.00E+00
        obesity III (BMI >= 40)                                     1.95 (0.96, 3.98)      0.6695   0.2196      2.29E-03          9.64E-02
        Not obese                                                      1                         0          nan          nan
        GENETIC SEX
        Female                                                         1                         0          nan          nan
        Male                                                         1.5 (0.95, 2.37)      0.4041     0.142     4.42E-03          1.85E-01
        SYMPTOMS
        Abdominal pain                                              2.03 (1.24, 3.32)      0.7095   0.1514      2.77E-06          1.16E-04
        Body aches                                                  1.88 (1.08, 3.27)      0.6321   0.1707      2.13E-04          8.95E-03
        Change in taste or smell                                    1.03 (0.63, 1.66)       0.025   0.1485      8.66E-01         1.00E+00
        Chills                                                      2.22 (1.35, 3.66)      0.7975   0.1542      2.31E-07          9.70E-06
        Cough producing phlegm                                      1.69 (1.05, 2.70)      0.5233   0.1452      3.14E-04          1.32E-02
        Diarrhea                                                    2.74 (1.71, 4.39)      1.0077   0.1457      4.58E-12          1.92E-10
        Dry cough                                                   2.73 (1.62, 4.59)      1.0041   0.1601      3.60E-10          1.51E-08
        Feeling tired or fatigue                                    2.86 (1.10, 7.40)         1.05  0.2938      3.51E-04          1.48E-02
        Fever                                                       3.34 (1.91, 5.85)      1.2074   0.1726      2.65E-12          1.11E-10
        Headache                                                    1.18 (0.72, 1.95)      0.1678   0.1537      2.75E-01         1.00E+00
        Nasal congestion                                            1.12 (0.70, 1.78)      0.1106   0.1435      4.41E-01         1.00E+00
        Nausea or vomiting                                          2.72 (1.65, 4.49)      0.9997   0.1547      1.03E-10          4.31E-09
        Runny nose                                                  1.19 (0.72, 1.95)      0.1704     0.153     2.65E-01         1.00E+00
        Shortness of breath                                        12.87 (6.18, 26.81)     2.5549   0.2265      1.62E-29          6.79E-28
        Sore throat                                                 1.65 (1.01, 2.68)      0.4991   0.1503      9.01E-04          3.79E-02
697
698     Adjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness
699     were calculated among those reporting a positive COVID-19 test result. The following groups
700     served as reference populations for the odds ratio calculations: European genetic ancestry
701     (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30,
702     Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
703     symptomatic customers only (Methods). Here, odds ratios were adjusted for age, sex,
704     comorbitidies (Y/N if any), and obesity (Y/N if BMI > 30, Methods).
                                                                            61

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
705     Supplementary Table 17. Unadjusted risk factor odds ratios for COVID-19 susceptibility
706     (training dataset)
        RISK FACTOR                                              ODDS      OR 95% CI       logOR    logOR     P-VALUE       P-VALUE
                                                                 RATIO     (BONFERRONI)             S.E.      (NOMINAL) (BONFERRONI)
                                                                 (OR)
        AGE
        Ages 18-29                                                     1.6 (1.21, 2.11)      0.4693   0.0857       4.42E-08        1.86E-06
        Ages 30-49                                                    1.11 (0.92, 1.34)       0.105   0.0584       7.22E-02        1.00E+00
        Ages 50-64                                                       1                        0           nan           nan
        Ages 65+                                                      0.49 (0.38, 0.63)     -0.7051     0.077      0.00E+00        0.00E+00
        GENETIC ANCESTRY
        Admixed African-European                                      1.24 (0.85, 1.81)      0.2158   0.1168       6.47E-02        1.00E+00
        European                                                         1                        0           nan           nan
        Admixed Amerindian                                            1.59 (1.22, 2.07)       0.462   0.0814       1.36E-08        5.73E-07
        Other                                                         1.16 (0.94, 1.44)      0.1516   0.0665       2.27E-02        9.52E-01
        EXPOSURE
        Any                                                           9.49 (7.65, 11.77)     2.2503   0.0665      4.79E-251       2.01E-249
        Biological relative tested positive                           5.74 (4.66, 7.07)      1.7467   0.0644      4.71E-162       1.98E-160
        Directly exposed to someone who tested positive               7.63 (6.33, 9.19)      2.0317   0.0576      4.44E-272       1.87E-270
        Healthcare worker directly exposed                            1.56 (1.29, 1.87)      0.4417   0.0576       1.78E-14        7.47E-13
        Household member tested positive                             24.28 (19.62, 30.03)    3.1896   0.0657       0.00E+00        0.00E+00
        PRE-EXISTING CONDITION
        Asthma                                                        0.81 (0.65, 1.00)     -0.2166   0.0677       1.37E-03        5.75E-02
        COPD (Chronic Obstructive Pulmonary Disease)                  0.54 (0.31, 0.93)     -0.6217   0.1684       2.22E-04        9.32E-03
        Cancer treated in the past year                               0.57 (0.32, 1.00)      -0.564   0.1731       1.12E-03        4.71E-02
        Cardiovascular disease                                        0.74 (0.51, 1.06)     -0.3014   0.1122       7.26E-03        3.05E-01
        Chronic kidney disease                                        0.55 (0.28, 1.10)     -0.5938   0.2139       5.49E-03        2.31E-01
        Diabetes                                                       0.9 (0.69, 1.17)      -0.105   0.0816       1.98E-01        1.00E+00
        Hypertension                                                  0.76 (0.62, 0.93)     -0.2728     0.061      7.64E-06        3.21E-04
        Other                                                         0.93 (0.66, 1.31)     -0.0726   0.1049       4.89E-01        1.00E+00
        Other autoimmune disease                                       0.8 (0.61, 1.04)     -0.2241     0.081      5.65E-03        2.37E-01
        Other immunodeficiency disorder                               0.77 (0.42, 1.40)     -0.2669   0.1854       1.50E-01        1.00E+00
        Other lung condition                                          0.64 (0.39, 1.03)     -0.4524   0.1502       2.59E-03        1.09E-01
                                                                              62

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Any                                                         0.67 (0.57, 0.79)     -0.3983   0.0498      1.33E-15          5.60E-14
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.02 (0.83, 1.25)      0.0212   0.0628      7.35E-01         1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.15 (0.94, 1.41)      0.1376   0.0626      2.81E-02         1.00E+00
        obesity III (BMI >= 40)                                     1.13 (0.85, 1.50)         0.12  0.0874      1.70E-01         1.00E+00
        Not obese                                                      1                         0          nan          nan
        GENETIC SEX
        Female                                                         1                         0          nan          nan
        Male                                                        1.16 (0.98, 1.37)      0.1459   0.0525      5.43E-03
                                                                                                                                  2.28E-01
        SYMPTOMS
        Abdominal pain                                              0.97 (0.64, 1.48)     -0.0303   0.1303      8.16E-01         1.00E+00
        Body aches                                                  1.56 (1.09, 2.23)      0.4461   0.1104      5.34E-05          2.24E-03
        Change in taste or smell                                    7.02 (4.67, 10.56)     1.9493   0.1257      2.96E-54          1.24E-52
        Chills                                                      1.38 (0.97, 1.96)      0.3211   0.1085      3.08E-03          1.29E-01
        Cough producing phlegm                                      0.93 (0.64, 1.37)     -0.0685   0.1178      5.61E-01         1.00E+00
        Diarrhea                                                    1.18 (0.81, 1.72)      0.1672   0.1158      1.49E-01         1.00E+00
        Dry cough                                                   1.29 (0.91, 1.84)      0.2578   0.1082      1.72E-02          7.21E-01
        Feeling tired or fatigue                                    1.54 (0.99, 2.42)      0.4341   0.1381      1.67E-03          7.03E-02
        Fever                                                       1.54 (1.08, 2.19)      0.4295   0.1088      7.84E-05          3.29E-03
        Headache                                                    1.39 (0.97, 2.00)         0.33  0.1118      3.17E-03          1.33E-01
        Nasal congestion                                            0.85 (0.60, 1.21)     -0.1632   0.1081      1.31E-01         1.00E+00
        Nausea or vomiting                                          0.82 (0.53, 1.26)     -0.1979   0.1327      1.36E-01         1.00E+00
        Runny nose                                                  0.59 (0.41, 0.86)     -0.5246   0.1137      3.92E-06          1.65E-04
        Shortness of breath                                         1.25 (0.87, 1.79)      0.2219   0.1106      4.48E-02         1.00E+00
        Sore throat                                                 0.48 (0.34, 0.69)     -0.7286   0.1117      6.84E-11          2.87E-09
707
708     Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants
709     reporting a test result (positive or negative). The following groups served as reference
710     populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
711     50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms
712     odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).
713
                                                                            63

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
714     Supplementary Table 18. Unadjusted risk factor odds ratios for COVID-19 hospitalization
715     (training dataset)
716
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.53 (0.20, 1.37)     -0.6395   0.2951      3.02E-02       1.00E+00
        Ages 30-49                                                     0.5 (0.27, 0.92)     -0.6907   0.1879      2.37E-04        9.95E-03
        Ages 50-64                                                       1                        0           nan          nan
        Ages 65+                                                      1.64 (0.87, 3.08)      0.4956   0.1943      1.07E-02        4.51E-01
        GENETIC ANCESTRY
        Admixed African-European                                      1.19 (0.43, 3.28)       0.176   0.3121      5.73E-01       1.00E+00
        European                                                         1                        0           nan          nan
        Admixed Amerindian                                            0.77 (0.32, 1.86)     -0.2551   0.2703      3.45E-01       1.00E+00
        Other                                                         0.69 (0.34, 1.39)     -0.3752   0.2169      8.37E-02       1.00E+00
        EXPOSURE
        Any                                                           0.69 (0.34, 1.39)     -0.3732   0.2174      8.61E-02       1.00E+00
        Biological relative tested positive                           1.06 (0.60, 1.88)      0.0572   0.1772      7.47E-01       1.00E+00
        Directly exposed to someone who tested positive               0.54 (0.29, 0.98)     -0.6207   0.1867      8.86E-04        3.72E-02
        Healthcare worker directly exposed                            0.57 (0.29, 1.10)     -0.5698   0.2042      5.26E-03        2.21E-01
        Household member tested positive                              0.88 (0.53, 1.45)     -0.1332   0.1551      3.90E-01       1.00E+00
        HEALTH CONDITIONS
        Asthma                                                        1.17 (0.62, 2.19)      0.1555   0.1944      4.24E-01       1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  2.95 (0.82, 10.67)      1.083   0.3962      6.27E-03        2.63E-01
        Cancer treated in the past year                               3.21 (0.88, 11.78)     1.1677   0.4006      3.56E-03        1.49E-01
        Cardiovascular disease                                        2.73 (1.18, 6.28)      1.0036   0.2573      9.62E-05        4.04E-03
        Chronic kidney disease                                       10.82 (2.86, 40.90)     2.3812   0.4103      6.49E-09        2.73E-07
        Diabetes                                                      3.21 (1.70, 6.06)      1.1676   0.1957      2.44E-09        1.02E-07
        Hypertension                                                  1.68 (0.98, 2.88)      0.5172   0.1664      1.88E-03        7.91E-02
        Other                                                         1.63 (0.74, 3.63)      0.4906   0.2463      4.64E-02       1.00E+00
        Other autoimmune disease                                      1.21 (0.58, 2.54)      0.1914   0.2288      4.03E-01       1.00E+00
        Other immunodeficiency disorder                               0.77 (0.11, 5.53)     -0.2655   0.6094      6.63E-01       1.00E+00
                                                                              64

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                                         1.8 (0.50, 6.55)      0.5883   0.3983       1.40E-01        1.00E+00
        Any                                                         2.36 (1.41, 3.93)      0.8574   0.1575       5.26E-08         2.21E-06
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.32 (0.74, 2.34)      0.2765   0.1771       1.19E-01        1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.08 (0.56, 2.06)      0.0753   0.2001       7.07E-01        1.00E+00
        obesity III (BMI >= 40)                                     1.42 (0.62, 3.26)      0.3505   0.2566       1.72E-01        1.00E+00
        Not obese                                                      1                        0            nan          nan
        GENETIC SEX
        Female                                                         1                        0            nan          nan
        Male                                                        1.29 (0.79, 2.12)      0.2584   0.1525       9.02E-02        1.00E+00
        SYMPTOMS
        Abdominal pain                                              1.79 (1.04, 3.10)      0.5841   0.1686       5.33E-04         2.24E-02
        Body aches                                                   1.6 (0.90, 2.83)      0.4695   0.1765       7.80E-03         3.28E-01
        Change in taste or smell                                    0.83 (0.50, 1.38)      -0.189   0.1582       2.32E-01        1.00E+00
        Chills                                                      2.18 (1.29, 3.71)      0.7814   0.1632       1.68E-06         7.07E-05
        Cough producing phlegm                                      1.51 (0.90, 2.53)      0.4096   0.1596       1.03E-02         4.31E-01
        Diarrhea                                                    2.04 (1.24, 3.36)      0.7114     0.154      3.87E-06         1.62E-04
        Dry cough                                                    2.5 (1.47, 4.28)      0.9179   0.1653       2.80E-08         1.18E-06
        Feeling tired or fatigue                                    4.47 (1.35, 14.73)     1.4965   0.3681       4.79E-05         2.01E-03
        Fever                                                       3.06 (1.72, 5.44)      1.1178     0.178      3.36E-10         1.41E-08
        Headache                                                    0.87 (0.52, 1.47)     -0.1351       0.16     3.99E-01        1.00E+00
        Nasal congestion                                            0.73 (0.44, 1.23)     -0.3139   0.1595       4.90E-02        1.00E+00
        Nausea or vomiting                                          2.48 (1.45, 4.23)      0.9068   0.1653       4.13E-08         1.74E-06
        Runny nose                                                  0.87 (0.49, 1.55)     -0.1355   0.1777       4.46E-01        1.00E+00
        Shortness of breath                                          6.4 (3.49, 11.73)     1.8558     0.187      3.34E-23         1.40E-21
        Sore throat                                                 1.03 (0.59, 1.80)      0.0332   0.1717       8.47E-01        1.00E+00
717
718     Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among
719     those reporting a positive COVID-19 test result. The following groups served as reference
720     populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages
721     50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms
722     odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).
723
                                                                            65

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                            It is made available under a CC-BY-NC-ND 4.0 International license .
724     Supplementary Table 19. Unadjusted risk factor odds ratios for progression of COVID-19
725     to a critical case (training dataset)
726
        RISK FACTOR                                               ODDS OR 95% CI           logOR    logOR     P-VALUE      P-VALUE
                                                                  RATIO (BONFERRONI)                S.E.      (NOMINAL) (BONFERRONI)
                                                                  (OR)
        AGE
        Ages 18-29                                                    0.48 (0.12, 1.84)     -0.7444   0.4175      7.46E-02       1.00E+00
        Ages 30-49                                                    0.61 (0.28, 1.33)     -0.4935   0.2408      4.04E-02       1.00E+00
        Ages 50-64                                                       1                        0           nan          nan
        Ages 65+                                                      1.32 (0.56, 3.12)      0.2779   0.2651      2.95E-01       1.00E+00
        GENETIC ANCESTRY
        Admixed African-European                                       2.2 (0.72, 6.73)      0.7892   0.3445      2.20E-02        9.24E-01
        European                                                         1                        0           nan          nan
        Admixed Amerindian                                            1.08 (0.36, 3.21)      0.0779   0.3354      8.16E-01       1.00E+00
        Other                                                         0.84 (0.34, 2.13)     -0.1692   0.2852      5.53E-01       1.00E+00
        EXPOSURE
        Any                                                           0.67 (0.26, 1.72)     -0.3951   0.2884      1.71E-01       1.00E+00
        Biological relative tested positive                           1.18 (0.56, 2.50)      0.1677   0.2304      4.67E-01       1.00E+00
        Directly exposed to someone who tested positive               0.46 (0.20, 1.03)     -0.7835   0.2502      1.74E-03        7.31E-02
        Healthcare worker directly exposed                            0.61 (0.25, 1.47)     -0.4938   0.2711      6.85E-02       1.00E+00
        Household member tested positive                              0.99 (0.51, 1.93)     -0.0064   0.2055      9.75E-01       1.00E+00
        PRE-EXISTING CONDITION
        Asthma                                                        1.04 (0.44, 2.46)      0.0353   0.2669      8.95E-01       1.00E+00
        COPD (Chronic Obstructive Pulmonary Disease)                  4.34 (1.06, 17.88)     1.4689   0.4366      7.66E-04        3.22E-02
        Cancer treated in the past year                               1.66 (0.23, 12.21)     0.5094   0.6149      4.07E-01       1.00E+00
        Cardiovascular disease                                        2.88 (1.03, 8.08)      1.0584     0.318     8.74E-04        3.67E-02
        Chronic kidney disease                                       13.83 (3.59, 53.34)     2.6267   0.4165      2.85E-10        1.20E-08
        Diabetes                                                      3.53 (1.61, 7.75)      1.2624   0.2422      1.86E-07        7.82E-06
        Hypertension                                                  2.16 (1.09, 4.29)      0.7721   0.2113      2.59E-04        1.09E-02
        Other                                                         1.64 (0.58, 4.63)      0.4926   0.3206      1.24E-01       1.00E+00
        Other autoimmune disease                                      1.28 (0.49, 3.36)      0.2478   0.2976      4.05E-01       1.00E+00
        Other immunodeficiency disorder                               2.16 (0.37, 12.54)     0.7723     0.542     1.54E-01       1.00E+00
                                                                              66

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
        Other lung condition                                        3.74 (1.01, 13.88)     1.3195   0.4045       1.10E-03         4.64E-02
        Any                                                         3.13 (1.52, 6.45)      1.1406   0.2233       3.25E-07         1.37E-05
        OBESITY
        obesity I (BMI >= 30 and BMI < 35)                          1.24 (0.57, 2.68)      0.2116   0.2385       3.75E-01        1.00E+00
        obesity II (BMI >= 35 and BMI < 40)                         1.12 (0.48, 2.62)      0.1104   0.2632       6.75E-01        1.00E+00
        obesity III (BMI >= 40)                                      1.5 (0.51, 4.38)      0.4053   0.3305       2.20E-01        1.00E+00
        Not obese                                                      1                        0            nan          nan
        GENETIC SEX
        Female                                                         1                        0            nan          nan
        Male                                                        1.53 (0.80, 2.94)      0.4266   0.2013       3.41E-02        1.00E+00
        SYMPTOMS
        Abdominal pain                                              2.02 (1.01, 4.06)      0.7042   0.2147       1.04E-03         4.37E-02
        Body aches                                                  2.16 (0.95, 4.93)      0.7723   0.2541       2.37E-03         9.95E-02
        Change in taste or smell                                    0.73 (0.37, 1.41)     -0.3191   0.2051       1.20E-01        1.00E+00
        Chills                                                      2.32 (1.14, 4.72)      0.8403   0.2196       1.30E-04         5.44E-03
        Cough producing phlegm                                      1.89 (0.97, 3.66)      0.6342   0.2046       1.94E-03         8.13E-02
        Diarrhea                                                    2.33 (1.21, 4.48)       0.844   0.2021       2.96E-05         1.24E-03
        Dry cough                                                   2.69 (1.30, 5.56)      0.9909   0.2238       9.53E-06         4.00E-04
        Feeling tired or fatigue                                    6.27 (0.93, 42.41)     1.8352       0.59     1.87E-03         7.84E-02
        Fever                                                       3.33 (1.50, 7.36)      1.2022   0.2449       9.18E-07         3.85E-05
        Headache                                                    0.86 (0.44, 1.70)     -0.1487   0.2098       4.78E-01        1.00E+00
        Nasal congestion                                            0.92 (0.48, 1.80)     -0.0791   0.2053       7.00E-01        1.00E+00
        Nausea or vomiting                                          2.43 (1.22, 4.84)      0.8874   0.2129       3.07E-05         1.29E-03
        Runny nose                                                  0.95 (0.45, 2.01)     -0.0495   0.2303       8.30E-01        1.00E+00
        Shortness of breath                                        10.57 (3.99, 28.02)     2.3584   0.3007       4.35E-15         1.83E-13
        Sore throat                                                 1.27 (0.63, 2.57)      0.2369   0.2177       2.76E-01        1.00E+00
727
728     Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening
729     illness were calculated among those reporting a positive COVID-19 test result. The following
730     groups served as reference populations for the odds ratio calculations: European genetic ancestry
731     (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30,
732     Obesity). Note that symptoms odds ratios were calculated in a binary fashion among
733     symptomatic customers only (Methods).
734
                                                                            67

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                           It is made available under a CC-BY-NC-ND 4.0 International license .
735     Supplementary Table 20. Summary of risk factors and performances of different models
736
737
        Model                          Risk Factors in Final Model                                                                            Holdout
                                                                                                                                              AUC
                                                                                                                                              (95% CI)
        Susceptibilityâ€“ symptoms       sex, aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker           0.84 (0.82,
        excluded (Dem + Exp)           directly exposed, Household member tested positive, Household positive case count, Biological          0.86)
                                       relative tested positive, Directly exposed to someone who tested positive
        Susceptibilityâ€“ symptoms       sex, Fever, Runny nose, Sore throat, Feeling tired or fatigue, Change in taste or smell, aged 18-29    0.94 (0.92,
        included                       (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker directly exposed,         0.96)
        (Dem + Exp + Symp)             Household member tested positive, Household positive case count, Biological relative tested
                                       positive, Directly exposed to someone who tested positive
        Susceptibilityâ€“ symptoms       aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly      0.86 (0.85,
        excluded, L1-penalized         exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed,              0.87)
        model across larger set of     Household positive case count, Household member tested positive, Health condition (Y/N if any)
        risk factors
        Susceptibilityâ€“ symptoms       aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly      0.90 (0.86,
        included, L1-penalized         exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed,              0.94)
        model across larger set of     Household positive case count, Household member tested positive, Health condition (Y/N if any),
        risk factors                   Abdominal pain, Body aches, Change in taste or smell, Chills, Cough producing phlegm, Diarrhea,
                                       Dry cough, Feeling tired or fatigue, Fever, Headache, Nasal congestion, Nausea or vomiting, Runny
                                       nose, Shortness of breath, Sore throat
        Susceptibilityâ€“ literature-                                                                                                           0.90 (0.88,
        based "minimal" model          Change in taste or smell, Household member tested positive, Directly exposed to someone who            0.93)
        (HWF Exp + Symp)               tested positive
        Susceptibilityâ€“ literature-                                                                                                           0.87 (0.84,
        based "symptoms-only"                                                                                                                 0.90)
        model (HWF Symp)
                                       Fever, Shortness of breath, Dry cough, Sore throat,Chills, Body aches, Change in taste or smell
        Severityâ€“ hospitalization      sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >=    0.87 (0.84,
                                       40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Health condition (Y/N 0.90)
                                       if any)
        Severityâ€“ hospitalization,     aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary                0.87 (0.86,
        L1-penalized model across      Disease), Cancer (treated in the past year), Cardiovascular disease, Chronic kidney disease, Diabetes, 0.88)
        larger set of risk factors     Hypertension, Other, Health condition (Y/N if any), Abdominal pain, Chills, Cough producing
                                       phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting, Shortness of
                                       breath
        Severityâ€“ critical case        sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >=    0.90 (0.87,
                                       40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Health condition (Y/N 0.93)
                                       if any)
        Severityâ€“ critical case, L1-   aged 30-49 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary Disease),                        0.89 (0.87,
        penalized model across         Cardiovascular disease, Chronic kidney disease, Diabetes, Hypertension, Other lung condition,          0.91)
        larger set of risk factors     Health condition (Y/N if any), Seasonal flu, sex, Abdominal pain, Body aches, Chills, Cough
                                       producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting,
                                       Shortness of breath
738
                                                                                68

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
739     Risk factors for models were selected based on literature as well as nominally significant odds
740     ratios within the training dataset (Methods). 95% confidence intervals for the area under the
741     curve (AUC) on the holdout dataset were estimated via bootstrapping (Methods).
742
                                                                          69

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
743     Supplementary Table 21. Stratified holdout performance assessment for a COVID-19
744     susceptibility model built from age, sex, and exposures (Dem + Exp)
745
        cohort                                          N     ncase ncontrol AUC               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry         228    38      190 0.88 (0.82, 0.94) 0.89 (0.80, 0.99) 0.65 (0.59, 0.72)
        All                                             4834    632     4202 0.84 (0.82, 0.86) 0.75 (0.72, 0.79) 0.76 (0.75, 0.78)
        European Genetic Ancestry                       3372    408     2964 0.84 (0.82, 0.87) 0.74 (0.70, 0.78) 0.79 (0.77, 0.80)
        Admixed Amerindian Genetic Ancestry               410    73      337 0.80 (0.74, 0.86) 0.74 (0.64, 0.84) 0.71 (0.66, 0.75)
        Other Genetic Ancestry                            824   113      711 0.83 (0.78, 0.87) 0.77 (0.69, 0.85) 0.71 (0.68, 0.75)
        Ages 18-29                                        340    74      266 0.83 (0.77, 0.89) 0.81 (0.72, 0.90) 0.65 (0.59, 0.71)
        Ages 30-49                                      1744    270     1474 0.80 (0.77, 0.83) 0.82 (0.77, 0.86) 0.59 (0.56, 0.61)
        Ages 50-65                                      1515    200     1315 0.85 (0.82, 0.88) 0.73 (0.67, 0.79) 0.81 (0.79, 0.83)
        Ages 65+                                        1235     88     1147 0.81 (0.75, 0.87) 0.57 (0.47, 0.67) 0.96 (0.95, 0.97)
        Female                                          3354    409     2945 0.83 (0.81, 0.85) 0.73 (0.68, 0.77) 0.77 (0.75, 0.79)
        Male                                            1480    223     1257 0.85 (0.82, 0.88) 0.81 (0.76, 0.86) 0.75 (0.73, 0.77)
746
747     Case/control status is defined based on a self-reported COVID-19 positive test result. The Dem +
748     Exp model includes questions about exposures, age, and sex (Supplementary Table 20). Metric
749     performance columns reflect mean and nominal 95% confidence intervals for each metric on an
750     internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic
751     (ROC) curves were constructed from predicted class probabilities of models trained on the entire
752     training dataset (Methods).
753
754
                                                                           70

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
755     Supplementary Table 22. Stratified holdout performance assessment for a COVID-19
756     susceptibility model built from age, sex, exposures, and symptoms (Dem + Exp + Symp)
757
        cohort                                          N     ncase ncontrol AUC               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry          96    12       84 0.96 (0.88, 1.00) 0.91 (0.75, 1.00) 0.92 (0.86, 0.98)
        All                                             2047    229     1818 0.94 (0.92, 0.96) 0.85 (0.80, 0.89) 0.91 (0.90, 0.93)
        European Genetic Ancestry                       1457    146     1311 0.93 (0.90, 0.96) 0.83 (0.77, 0.90) 0.91 (0.90, 0.93)
        Admixed Amerindian Genetic Ancestry               155    23      132 0.98 (0.95, 1.00) 0.96 (0.87, 1.00) 0.89 (0.84, 0.95)
        Other Genetic Ancestry                            339    48      291 0.94 (0.90, 0.99) 0.81 (0.70, 0.92) 0.93 (0.90, 0.96)
        Ages 18-29                                        132    29      103 0.98 (0.95, 1.00) 0.93 (0.84, 1.00) 0.92 (0.87, 0.97)
        Ages 30-49                                        582    77      505 0.96 (0.95, 0.98) 0.89 (0.82, 0.96) 0.88 (0.85, 0.91)
        Ages 50-65                                        616    83      533 0.93 (0.90, 0.97) 0.84 (0.76, 0.92) 0.91 (0.88, 0.93)
        Ages 65+                                          717    40      677 0.89 (0.83, 0.96) 0.72 (0.58, 0.86) 0.95 (0.93, 0.97)
        Female                                          1380    139     1241 0.94 (0.91, 0.97) 0.86 (0.80, 0.92) 0.91 (0.89, 0.92)
        Male                                              667    90      577 0.94 (0.90, 0.97) 0.83 (0.76, 0.91) 0.93 (0.91, 0.96)
758
759     Case/control status is defined based on self-reported COVID-19 positive test result. The Dem +
760     Exp + Symp model includes questions about exposures, age, sex, and five symptom questions
761     (Supplementary Table 20). Metric performance columns reflect mean and nominal 95%
762     confidence intervals for each metric on an internal, independent holdout dataset (Methods).
763     Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class
764     probabilities of models trained on the entire training dataset (Methods).
765
766
767
                                                                           71

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
768     Supplementary Table 23. Stratified holdout performance assessment for a literature-based
769     COVID-19 susceptibility model based on two exposures and one symptom (HWF Exp +
770     Symp)
771
772
        cohort                                          N     ncase ncontrol AUC               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry          96    12       84 0.94 (0.84, 1.00) 0.92 (0.76, 1.00) 0.94 (0.89, 0.99)
        All                                             2047    229     1818 0.90 (0.88, 0.93) 0.78 (0.73, 0.83) 0.94 (0.93, 0.95)
        European Genetic Ancestry                       1457    146     1311 0.89 (0.86, 0.92) 0.75 (0.68, 0.82) 0.94 (0.93, 0.95)
        Admixed Amerindian Genetic Ancestry               155    23      132 0.94 (0.88, 1.00) 0.87 (0.73, 1.00) 0.92 (0.87, 0.97)
        Other Genetic Ancestry                            339    48      291 0.92 (0.87, 0.97) 0.79 (0.68, 0.90) 0.96 (0.94, 0.98)
        Ages 18-29                                        132    29      103 0.92 (0.85, 0.99) 0.79 (0.65, 0.94) 0.96 (0.92, 1.00)
        Ages 30-49                                        582    77      505 0.91 (0.86, 0.95) 0.82 (0.73, 0.91) 0.92 (0.90, 0.95)
        Ages 50-65                                        616    83      533 0.91 (0.87, 0.95) 0.81 (0.73, 0.89) 0.93 (0.91, 0.95)
        Ages 65+                                          717    40      677 0.85 (0.77, 0.92) 0.65 (0.50, 0.80) 0.96 (0.95, 0.98)
        Female                                          1380    139     1241 0.91 (0.88, 0.94) 0.81 (0.75, 0.88) 0.94 (0.92, 0.95)
        Male                                              667    90      577 0.89 (0.85, 0.94) 0.73 (0.64, 0.83) 0.95 (0.94, 0.97)
773     Case/control status is defined based on self-reported COVID-19 positive test result. The
774     literature-based HWF Exp + Symp model contains two exposure questions and a question about
775     one symptom (change in taste or smell, Supplementary Table 20).18 Metric performance columns
776     reflect mean and nominal 95% confidence intervals for each metric on an internal, independent
777     holdout dataset (Methods). Cohort-level receiver operator characteristic (ROC) curves were
778     constructed from predicted class probabilities of models trained on the entire training dataset
779     (Methods).
780
781
782
783
784
                                                                           72

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
785     Supplementary Table 24. Stratified holdout performance assessment for a literature-based
786     COVID-19 susceptibility model based on seven symptoms (HWF Symp)
787
788
        cohort                                          N     ncase ncontrol AUC               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry          96    12       84 0.90 (0.77, 1.00) 0.84 (0.62, 1.00) 0.92 (0.86, 0.98)
        All                                             2047    229     1818 0.87 (0.84, 0.90) 0.75 (0.69, 0.80) 0.91 (0.90, 0.93)
        European Genetic Ancestry                       1457    146     1311 0.87 (0.83, 0.91) 0.75 (0.68, 0.82) 0.91 (0.89, 0.93)
        Admixed Amerindian Genetic Ancestry               155    23      132 0.92 (0.85, 0.99) 0.87 (0.73, 1.00) 0.93 (0.89, 0.97)
        Other Genetic Ancestry                            339    48      291 0.83 (0.76, 0.91) 0.67 (0.53, 0.80) 0.92 (0.89, 0.95)
        Ages 18-29                                        132    29      103 0.85 (0.75, 0.96) 0.79 (0.64, 0.95) 0.94 (0.90, 0.99)
        Ages 30-49                                        582    77      505 0.89 (0.85, 0.93) 0.75 (0.66, 0.85) 0.88 (0.85, 0.91)
        Ages 50-65                                        616    83      533 0.86 (0.80, 0.91) 0.75 (0.65, 0.84) 0.89 (0.87, 0.92)
        Ages 65+                                          717    40      677 0.84 (0.76, 0.92) 0.70 (0.55, 0.85) 0.95 (0.93, 0.96)
        Female                                          1380    139     1241 0.87 (0.83, 0.91) 0.76 (0.69, 0.83) 0.90 (0.88, 0.92)
        Male                                              667    90      577 0.87 (0.83, 0.92) 0.73 (0.63, 0.82) 0.94 (0.92, 0.96)
789     Case/control status is defined based on self-reported COVID-19 positive test result. The
790     literature-based HWF Symp model contains 7 symptoms most commonly associated with
791     COVID-19 (Supplementary Table 20).18 Metric performance columns reflect mean and nominal
792     95% confidence intervals for each metric on an internal, independent holdout dataset (Methods).
793     Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class
794     probabilities of models trained on the entire training dataset (Methods).
795
                                                                           73

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
796     Supplementary Table 25. Comparison between train and holdout performances for
797     different risk models
798
799
        Model                                                                 Train AUC (95% CI) Holdout AUC (95% CI)
        Susceptibilityâ€“ no symptoms (Dem + Exp)                               0.83 (0.81, 0.85)    0.84 (0.82, 0.84)
        Susceptibilityâ€“ with symptoms (Dem + Exp + Symp)                      0.95 (0.93, 0.97)    0.94 (0.92, 0.96)
        Susceptibilityâ€“ literature-based "minimal" model (HWF Exp + Symp) 0.90 (0.88, 0.92)        0.90 (0.88, 0.93)
        Susceptibilityâ€“ literature-based "symptoms-only" model (HWF Symp) 0.87 (0.84, 0.90)        0.87 (0.84, 0.90)
        Severityâ€“ hospitalization                                             0.85 (0.82, 0.88)    0.87 (0.84, 0.90)
        Severityâ€“ critical case of COVID-19                                   0.90 (0.87, 0.93)    0.90 (0.87, 0.93)
800
801     Columns reflect mean and nominal 95% confidence intervals for the area under the curve (AUC)
802     of trained models on either the training or holdout dataset. Confidence intervals were estimated
803     via bootstrapping (Methods).
804
                                                                          74

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
805     Supplementary Table 26. Stratified holdout performance assessment for models to predict
806     hospitalization amongst COVID-19 positive cases
807
        cohort                                          N     ncase ncontrol Auc               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry         110    20       90 0.81 (0.72, 0.90) 0.85 (0.68, 1.00) 0.71 (0.62, 0.80)
        All                                             1793    191     1602 0.87 (0.84, 0.90) 0.83 (0.78, 0.88) 0.75 (0.73, 0.77)
        European Genetic Ancestry                       1133    120     1013 0.87 (0.84, 0.90) 0.82 (0.76, 0.89) 0.74 (0.72, 0.77)
        Admixed Amerindian Genetic Ancestry               219    16      203 0.94 (0.90, 0.98) 0.93 (0.81, 1.00) 0.79 (0.74, 0.85)
        Other Genetic Ancestry                            331    35      296 0.85 (0.77, 0.93) 0.80 (0.67, 0.94) 0.75 (0.70, 0.80)
        Ages 18-29                                        201     7      194 0.95 (0.91, 0.99) 0.85 (0.57, 1.00) 0.90 (0.85, 0.94)
        Ages 30-49                                        705    49      656 0.87 (0.82, 0.93) 0.76 (0.63, 0.88) 0.85 (0.82, 0.88)
        Ages 50-65                                        616    78      538 0.86 (0.81, 0.90) 0.86 (0.78, 0.94) 0.65 (0.61, 0.69)
        Ages 65+                                          271    57      214 0.78 (0.72, 0.85) 0.86 (0.77, 0.95) 0.53 (0.47, 0.60)
        Female                                          1166    118     1048 0.87 (0.83, 0.90) 0.80 (0.72, 0.87) 0.77 (0.74, 0.79)
        Male                                              627    73      554 0.87 (0.83, 0.91) 0.89 (0.82, 0.96) 0.71 (0.67, 0.75)
808
809     Case/control status is defined based on self-reported hospitalization due to COVID-19-related
810     illness (Methods). Metric performance columns reflect mean and nominal 95% confidence
811     intervals for each metric on an internal, independent holdout dataset (Methods). Cohort-level
812     receiver operator characteristic (ROC) curves were constructed from predicted class probabilities
813     of models trained on the entire survey cohort (Methods).
814
815
                                                                           75

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
816     Supplementary Table 27. Stratified holdout performance assessment for models to predict
817     critical COVID-19 cases amongst all COVID-19 positive cases
818
        cohort                                          N     ncase ncontrol AUC               Sensitivity       Specificity
        Admixed African-European Genetic Ancestry         110    15       95 0.87 (0.78, 0.97) 0.93 (0.80, 1.00) 0.75 (0.66, 0.83)
        All                                             1793    105     1688 0.90 (0.87, 0.93) 0.93 (0.87, 0.98) 0.79 (0.77, 0.81)
        European Genetic Ancestry                       1133     70     1063 0.90 (0.86, 0.93) 0.90 (0.83, 0.97) 0.79 (0.76, 0.81)
        Admixed Amerindian Genetic Ancestry               219     7      212 0.92 (0.88, 0.96) 1.00 (0.60, 1.00) 0.83 (0.78, 0.88)
        Other Genetic Ancestry                            331    13      318 0.92 (0.87, 0.97) 1.00 (0.73, 1.00) 0.77 (0.73, 0.82)
        Ages 18-29                                        201     2      199 0.96 (0.92, 0.99) 1.00 (0.29, 1.00) 0.92 (0.88, 0.96)
        Ages 30-49                                        705    24      681 0.94 (0.92, 0.96) 1.00 (0.84 1.00) 0.84 (0.81, 0.87)
        Ages 50-65                                        616    43      573 0.87 (0.82, 0.93) 0.91 (0.82, 0.99) 0.71 (0.68, 0.75)
        Ages 65+                                          271    36      235 0.84 (0.78, 0.91) 0.89 (0.78, 0.99) 0.71 (0.66, 0.77)
        Female                                          1166     60     1106 0.90 (0.86, 0.94) 0.93 (0.87, 1.00) 0.80 (0.77, 0.83)
        Male                                              627    45      582 0.89 (0.85, 0.93) 0.91 (0.83, 0.99) 0.77 (0.73, 0.80)
819
820     Case/control status is defined based on self-reported critical case progression among all COVID-
821     19 cases. Here, a critical case is defined based on self-reported ICU admittance, respiratory
822     failure, organ failure, or septic shock resulting from COVID-19-related illness (Methods). Metric
823     performance columns reflect mean and nominal 95% confidence intervals for each metric on an
824     internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic
825     (ROC) curves were constructed from predicted class probabilities of models trained on the entire
826     survey cohort (Methods).
827
828
829
                                                                           76

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
830     Supplementary Figures
831
                                                                          77

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
832     Supplementary Figure 1. Severity (critical case) odds ratios (ORs) and 95% confidence
833     intervals (CIs) estimated from simple (â€œUnadjusted models,â€ grey) and multiple
834     (â€œAdjusted models,â€ black) logistic regression with adjustment for other risk factors. Open
835     circles indicate not significant (p-value > 0.05) after accounting for multiple hypothesis tests
836     using Bonferroni correction. Age, sex, genetic ancestry, and obesity ORs were estimated in
837     relation to the reference variables indicated. Exposure, health, and symptom ORs were each
838     estimated separately as binary variables. Symptom ORs were estimated as binary variables
839     among symptomatic testers only (Methods). Risk factor adjustments for severity include: sex,
840     age, obesity (Y/N), and underlying health conditions (Y/N if any). Where applicable, individual
841     adjustment variables were omitted to avoid duplicate adjustment (Methods).
842
                                                                          78

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
843
                                                                          79

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
844
                                                                          80

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
845
                                                                          81

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
846     Supplementary Figure 2: Comparison of Susceptibility and Severity adjusted ORs.
847     Comparison of susceptibility ORs (horizontal axis) and severity ORs (vertical axis) from Figures
848     1 and 2. Severity aORs are for hospitalization. aORs are adjusted as in Figures 1 and 2 (see Fig 3
849     for adjusted ORs for symptoms). Plotted on a log scale for visibility. (a) Demographics, broken
850     down by age, sex, and genetic ancestry. (b) Health conditions: Some pre-existing health
851     conditions have increased odds of critical outcomes but susceptibility is not characterized by
852     health conditions. (c) Exposures are important for susceptibility but not severity.
853
                                                                          82

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
854
855     Supplementary Figure 3: Risk model confusion matrices for independent holdout data.
856     Numbers represent number of individuals in each category. a) Susceptibility model with
857     demographics, exposures, and symptoms. b) Susceptibility model demographics and exposures
858     (symptoms excluded). c) Literature-based susceptibility model with three risk factors including
859     two exposures and change in taste or smell. d) Literature-based susceptibility model with seven
860     COVID-19 symptoms. e) Hospitalization risk model. f) Critical case risk model. Refer to
861     Methods as well as Supplementary Tables 20-27 for additional model performance data and
862     model risk factor information.
                                                                          83

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
863
864
865     Supplementary Figure 4. Performance of susceptibility models evaluated in a symptomatic                                          tic
866     cohort of positive and negative testers. Plot depicts receiver operating characteristic (ROC)                                    C)
867     curves for four susceptibility models (Supplementary Table 20). Here, the modeling cohort has                                     as
868     been restricted to positive and negative testers reporting at least one symptom of moderate or
869     greater intensity for model training and evaluation.
870
                                                                          84

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
871
872     Supplementary Figure 5. Severity Models Excluding Dyspnea (Shortness of Breath). a)
873     Receiver operating characteristic (ROC) curves for severity models to predict either critical                                   cal
874     illness progression (black) or hospitalization (red) among COVID-19 positive cases. The models                                   els
875     here are built with the same risk factors as in Figure 4 with the exclusion of dyspnea (shortness                                 ss
876     of breath). b) Classification confusion matrix for severity models. Refer to Methods as well as
877     Supplementary Tables 20 for additional model risk factor information.
                                                                          85

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
878     References
879     1. Williamson, E. J. et al. Factors associated with COVID-19-related death using
880          OpenSAFELY. Nature 584, 430â€“436 (2020).
881     2. World Health Organization. Coronavirus Disease (COVID-19)â€“ Weekly Epidemiological
882          Update. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201005-
883          weekly-epi-update-8.pdf (2020).
884     3. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-
885          19): CDC COVID data tracker. https://covid.cdc.gov/covid-data-
886          tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-
887          ncov%2Fcases-updates%2Fcases-in-us.html#cases (2020).
888     4. CMMID COVID-19 working group et al. Age-dependent effects in the transmission and
889          control of COVID-19 epidemics. Nat. Med. 26, 1205â€“1211 (2020).
890     5. Yale IMPACT research team et al. Sex differences in immune responses that underlie
891          COVID-19 disease outcomes. Nature (2020) doi:10.1038/s41586-020-2700-3.
892     6. Roberts, G. H. L. & Park, D. S. AncestryDNA COVID-19 Host Genetic Study Identifies
893          Three Novel Loci. medRXiv (2020).
894     7. Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2.
895          medRXiv (2020) doi:10.1101/2020.01.26.919985.
896     8. Liu, Y. et al. Association between age and clinical characteristics and outcomes of COVID-
897          19. Eur. Respir. J. 55, 2001112 (2020).
898     9. Li, X. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.
899          J. Allergy Clin. Immunol. 146, 110â€“118 (2020).
                                                                          86

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
900     10. Clark, A. et al. Global, regional, and national estimates of the population at increased risk of
901          severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet
902          Glob. Health 8, e1003â€“e1017 (2020).
903     11. Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. & Klein, S. L. Impact of
904          sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 11, 29 (2020).
905     12. Grasselli, G. et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With
906          SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323, 1574 (2020).
907     13. Richardson, S. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700
908          Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323, 2052 (2020).
909     14. Guan, W. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a
910          nationwide analysis. Eur. Respir. J. 55, 2000547 (2020).
911     15. Ellinghaus, D. et al. Genomewide Association Study of Severe Covid-19 with Respiratory
912          Failure. N. Engl. J. Med. NEJMoa2020283 (2020) doi:10.1056/NEJMoa2020283.
913     16. Wynants, L. et al. Prediction models for diagnosis and prognosis of covid-19: systematic
914          review and critical appraisal. BMJ m1328 (2020) doi:10.1136/bmj.m1328.
915     17. Menni, C. et al. Real-time tracking of self-reported symptoms to predict potential COVID-
916          19. Nat. Med. 26, 1037â€“1040 (2020).
917     18. Allen, W. E. et al. Population-scale longitudinal mapping of COVID-19 symptoms,
918          behaviour and testing. Nat. Hum. Behav. 4, 972â€“982 (2020).
919     19. Martin, L. M., Leff, M., Garrett, C. & Nelson, D. E. Validation of self-reported chronic
920          conditions and health services in a managed care population. Am J Prev Med 18, 215â€“8
921          (2000).
                                                                          87

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
922     20. Nguyen, L. H. et al. Risk of COVID-19 among front-line health-care workers and the
923          general community: a prospective cohort study. Lancet Public Health 5, e475â€“e483 (2020).
924     21. Stokes, E. K. et al. Coronavirus Disease 2019 Case Surveillance â€” United States, January
925          22â€“May 30, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 759â€“765 (2020).
926     22. Chow, E. J. et al. Symptom Screening at Illness Onset of Health Care Personnel With SARS-
927          CoV-2 Infection in King County, Washington. JAMA 323, 2087 (2020).
928     23. Shi, L., Wang, Y., Wang, Y., Duan, G. & Yang, H. Dyspnea rather than fever is a risk factor
929          for predicting mortality in patients with COVID-19. J. Infect. S0163445320302887 (2020)
930          doi:10.1016/j.jinf.2020.05.013.
931     24. Jehi, L. et al. Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing.
932          Chest S0012369220316548 (2020) doi:10.1016/j.chest.2020.05.580.
933     25. Barreto, M. L. Infectious diseases epidemiology. J. Epidemiol. Community Health 60, 192â€“
934          195 (2006).
935     26. Rosenberg, A., Keene, D. E., Schlesinger, P., Groves, A. K. & Blankenship, K. M. COVID-
936          19 and Hidden Housing Vulnerabilities: Implications for Health Equity, New Haven,
937          Connecticut. AIDS Behav. 24, 2007â€“2008 (2020).
938     27. Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality
939          among Black Patients and White Patients with Covid-19. N. Engl. J. Med. 382, 2534â€“2543
940          (2020).
941     28. Millett, G. A. et al. Assessing differential impacts of COVID-19 on black communities. Ann.
942          Epidemiol. 47, 37â€“44 (2020).
943     29. Webb Hooper, M., NÃ¡poles, A. M. & PÃ©rez-Stable, E. J. COVID-19 and Racial/Ethnic
944          Disparities. JAMA 323, 2466 (2020).
                                                                          88

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
945     30. Julie Bosman & Mervosch, S. As virus surges, younger people account for â€˜disturbingâ€™
946          number of cases. The New York Times (2020).
947     31. Jehi, L. et al. Development and validation of a model for individualized prediction of
948          hospitalization risk in 4,536 patients with COVID-19. PLOS ONE 15, e0237419 (2020).
949     32. Dietz, W. & SantosBurgoa, C. Obesity and its Implications for COVID19 Mortality.
950          Obesity 28, 1005â€“1005 (2020).
951     33. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease: people with
952          certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-
953          precautions/people-with-medical-
954          conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F20
955          19-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html (2020).
956     34. U.S. Centers for Disease Control and Prevention (CDC). Coronavirus disease: scientific
957          evidence for conditions that increase risk of severe illness.
958          https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
959          (2020).
960     35. Han, E. et al. Clustering of 770,000 genomes reveals post-colonial population structure of
961          North America. Nat. Commun. 8, 14238 (2017).
962     36. Ball, C. A. Ethnicity Estimate 2019 White Paper.
963          https://www.ancestrycdn.com/dna/static/pdf/whitepapers/EV2019_white_paper_2.pdf
964          (2019).
965     37. Hastie, T. The Elements of Statistical Learning: Data Mining, Inference, and Prediction.
966          (Springer, 2009).
                                                                          89

    medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209593.this version posted October 16, 2020. The copyright holder for this preprint
      (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
                                          It is made available under a CC-BY-NC-ND 4.0 International license .
967     38. U.S. Centers for Disease Control and Prevention (CDC). Symptoms of Coronavirus.
968          https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (2020).
969     39. Jing, Q.-L. et al. Household secondary attack rate of COVID-19 and associated determinants
970          in Guangzhou, China: a retrospective cohort study. Lancet Infect. Dis. S1473309920304710
971          (2020) doi:10.1016/S1473-3099(20)30471-0.
972     40. Hu, Z. et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened
973          among close contacts in Nanjing, China. 6 (2020).
974
                                                                          90
